DNA-encoded bispecific T cell engagers targeting cancer antigens and methods of use in cancer therapeutics

Abstract

Disclosed herein are compositions comprising recombinant nucleic acid sequences encoding bispecific immune cell-engaging antibodies (DICE), recombinant nucleic acid sequences encoding bispecific T cell-engaging (DBiTE) antibodies, fragments thereof, variants thereof, or combinations thereof.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 798,626, filed January 30, 2019, and U.S. Provisional Application No. 62 / 827,265, filed April 1, 2019, each of which is incorporated by reference in its entirety herein.

[0002] The present invention relates to compositions comprising recombinant nucleic acid sequences for generating one or more synthetic DNA-encoded bispecific T cell engagers (BiTEs) and functional fragments thereof in vivo, and methods of preventing and / or treating cancer in a subject by administering said compositions. [Background technology]

[0003] Monoclonal antibody therapy has been a game changer in cancer therapeutics, but this treatment has several limitations, including the need for repeated administration, more limited stability, and cost. A further advancement in monoclonal technology is the development of bispecific T cell engagers (BiTEs), which combine the specificity of monoclonal antibodies with the cytotoxic potential of T cells. BiTEs have shown promising results in clinical trials for leukemia (Viardot et al., 2016, Blood, 127(11):1410-6; Goebeler et al., 2016, J Clin Oncol, 34(10):1104-11), however, this therapy requires continuous intravenous infusion for 4-8 weeks per cycle (Zhu et al., 2016, Clin Pharmacokinet, 55(10):1271-88) and may be limited in its production, limiting its applicability. Longer-lived and simpler production methods of antibody-based products could be important new tools for cancer immunotherapy.

[0004] Thus, there is a need in the art for longer-lived, simpler to produce, antibody-based products for cancer immunotherapy. The present invention meets this need. Summary of the Invention

[0005] In one embodiment, the present invention relates to nucleic acid molecules encoding one or more synthetic DNA encoded bispecific immune cell engagers comprising at least one antigen binding domain and at least one immune cell engaging domain.

[0006] In one embodiment, the antigen binding domain targets CD19, B-cell maturation antigen (BCMA), CD33, fibroblast activation protein (FAP), follicle-stimulating hormone receptor (FSHR), epidermal growth factor receptor (EGFR), prostate-specific membrane antigen (PSMA), CD123, or Her2.

[0007] In one embodiment, the immune cell engaging domain targets T cells, antigen presenting cells, natural killer (NK) cells, neutrophils, or macrophages.

[0008] In one embodiment, the immune cell engaging domain targets CD3, T cell receptor (TCR), CD28, CD16, NKG2D, Ox40, 4-1BB, CD2, CD5, CD40, FcgR, FceR, FcaR, or CD95. In one embodiment, the immune cell engaging domain targets CD3.

[0009] In one embodiment, the nucleic acid molecule comprises a nucleotide sequence encoding one or more sequences selected from: a) SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:6 0, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74 or SEQ ID NO:76, b) an amino acid sequence having at least about 90% identity over the entire length of the amino acid sequence to an amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:5 0, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74 or SEQ ID NO:76; c) an amino acid sequence having at least about 90% identity over at least 65% of the amino acid sequence to an amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74 or SEQ ID NO:76; 8, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74 or SEQ ID NO:76, and d) the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40,A fragment of an amino acid sequence comprising at least 65% of an amino acid sequence selected from SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74 or SEQ ID NO:76.

[0010] In one embodiment, the nucleic acid molecule comprises: a) SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73 and SEQ ID NO:75; b) a nucleotide sequence having at least about 90% identity over the entire length of the nucleic acid sequence to a nucleotide sequence selected from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO: 53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, and SEQ ID NO:75; c) a fragment of a nucleotide sequence having at least about 90% identity over at least 65% of the nucleic acid sequence to a nucleotide sequence selected from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37; or d) the nucleotide sequences of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37,A fragment of a nucleotide sequence comprising at least 65% of a nucleotide sequence selected from SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, and SEQ ID NO:75.

[0011] In one embodiment, the nucleotide sequence is operably linked to a nucleic acid sequence encoding an IgE leader sequence.

[0012] In one embodiment, the nucleic acid molecule comprises an expression vector.

[0013] In one embodiment, the present invention relates to a composition comprising a nucleic acid molecule encoding one or more synthetic DNA encoded bispecific immune cell engagers, the synthetic DNA encoded bispecific immune cell engagers comprising at least one antigen binding domain and at least one immune cell engaging domain. In one embodiment, the composition further comprises a pharma- ceutically acceptable excipient.

[0014] In one embodiment, the invention relates to a method of preventing or treating a disease or disorder in a subject, comprising administering to the subject a nucleic acid molecule encoding one or more synthetic DNA encoded bispecific immune cell engagers, or a composition comprising a nucleic acid molecule encoding one or more synthetic DNA encoded bispecific immune cell engagers, wherein the synthetic DNA encoded bispecific immune cell engagers comprise at least one antigen binding domain and at least one immune cell engaging domain. In one embodiment, the disease is a benign tumor, cancer, or a cancer-related disease.

[0015] In one embodiment, the invention relates to a nucleic acid molecule encoding one or more synthetic antibodies, the nucleic acid molecule comprising a nucleotide sequence encoding an anti-human epidermal growth factor receptor 2 (HER2) synthetic antibody, a nucleotide sequence encoding a fragment of an anti-HER2 synthetic antibody, a nucleotide sequence encoding an ScFv anti-HER2 synthetic antibody, or a nucleotide sequence encoding a fragment of an ScFv anti-HER2 synthetic antibody.

[0016] In one embodiment, the nucleotide sequence encodes an amino acid sequence having at least about 90% identity over the entire length of the amino acid sequence to SEQ ID NO:62, SEQ ID NO:64, or SEQ ID NO:66. In one embodiment, the nucleotide sequence encodes a fragment of an amino acid sequence having at least about 90% identity over at least 65% of the amino acid sequence to SEQ ID NO:62, SEQ ID NO:64, or SEQ ID NO:66. In one embodiment, the nucleotide sequence encodes the amino acid sequence of SEQ ID NO:62, SEQ ID NO:64, or SEQ ID NO:66. In one embodiment, the nucleotide sequence encodes a fragment of an amino acid sequence comprising at least 65% of SEQ ID NO:62, SEQ ID NO:64, or SEQ ID NO:66.

[0017] In one embodiment, the nucleic acid molecule comprises a nucleotide sequence having at least about 90% identity over the entire length of SEQ ID NO:61, SEQ ID NO:63, or SEQ ID NO:65. In one embodiment, the nucleic acid molecule comprises a fragment of a nucleotide sequence having at least about 90% identity over at least 65% of the nucleic acid sequence to the nucleotide sequence of SEQ ID NO:61, SEQ ID NO:63, or SEQ ID NO:65. In one embodiment, the nucleic acid molecule comprises a selected nucleotide sequence of SEQ ID NO:61, SEQ ID NO:63, or SEQ ID NO:65. In one embodiment, the nucleic acid molecule comprises a fragment of a nucleotide sequence comprising at least 65% of the nucleotide sequence of SEQ ID NO:61, SEQ ID NO:63, or SEQ ID NO:65.

[0018] In one embodiment, the nucleotide sequence is operably linked to a nucleic acid sequence encoding an IgE leader sequence.

[0019] In one embodiment, the nucleic acid molecule comprises an expression vector.

[0020] In one embodiment, the present invention relates to a composition comprising a nucleic acid molecule encoding one or more synthetic antibodies, the nucleic acid molecule comprising a nucleotide sequence encoding an anti-human epidermal growth factor receptor 2 (HER2) synthetic antibody, a nucleotide sequence encoding a fragment of an anti-HER2 synthetic antibody, a nucleotide sequence encoding an ScFv anti-HER2 synthetic antibody, or a nucleotide sequence encoding a fragment of an ScFv anti-HER2 synthetic antibody. In one embodiment, the composition further comprises a pharma- ceutically acceptable excipient.

[0021] In one embodiment, the invention relates to a method for preventing or treating a disease in a subject, comprising administering to the subject a nucleic acid molecule encoding one or more synthetic antibodies, wherein the nucleic acid molecule comprises a nucleotide sequence encoding an anti-human epidermal growth factor receptor 2 (HER2) synthetic antibody, a nucleotide sequence encoding a fragment of an anti-HER2 synthetic antibody, a nucleotide sequence encoding an ScFv anti-HER2 synthetic antibody, or a nucleotide sequence encoding a fragment of an ScFv anti-HER2 synthetic antibody.

[0022] In one embodiment, the present invention relates to a method for preventing or treating a disease in a subject, comprising administering to the subject a nucleic acid molecule encoding one or more synthetic antibodies, the nucleic acid molecule comprising a nucleotide sequence encoding an anti-human epidermal growth factor receptor 2 (HER2) synthetic antibody, a nucleotide sequence encoding a fragment of an anti-HER2 synthetic antibody, a nucleotide sequence encoding an ScFv anti-HER2 synthetic antibody, or a nucleotide sequence encoding a fragment of an ScFv anti-HER2 synthetic antibody. In one embodiment, the disease is a cancer associated with HER2 expression. In one embodiment, the disease is ovarian cancer or breast cancer.

[0023] In one embodiment, the present invention relates to a method for preventing or treating a disease in a subject, comprising administering to the subject a composition comprising a nucleic acid molecule encoding one or more synthetic antibodies, the nucleic acid molecule comprising a nucleotide sequence encoding an anti-human epidermal growth factor receptor 2 (HER2) synthetic antibody, a nucleotide sequence encoding a fragment of an anti-HER2 synthetic antibody, a nucleotide sequence encoding an ScFv anti-HER2 synthetic antibody, or a nucleotide sequence encoding a fragment of an ScFv anti-HER2 synthetic antibody. In one embodiment, the disease is a cancer associated with HER2 expression. In one embodiment, the disease is ovarian cancer or breast cancer. [Brief description of the drawings]

[0024] [Figure 1] 1 shows an exemplary Western blot of supernatants of 293T cells transfected with BCMADBiTE, CD33DBiTE, and CD123DBiTE. [Diagram 2] 1 shows an exemplary Western blot of supernatants of 293T cells transfected with EGFRvIIIDBiTE, FSHRDBiTE, PSMADBiTE, and CD19DBiTE. [Diagram 3] Diagram of experimental design. PBMCs from three independent donors were cultured in triplicate for 5 h in the presence of 5 μl of CD19DBiTE or control DBiTE (EGFRvIIIDBiTE) supernatant. After incubation, cells were stained for B and T cell markers to determine potential cytolytic activity against early activation of B cells (CD19+ cells) and T cells. [Figure 4] 1 shows the results of an exemplary experiment demonstrating that all three donors showed depletion of B cells (CD19+ cells in the PBMC mixture) in the presence of CD19DBiTE, but not in the presence of control DBiTE. [Diagram 5] 1 shows the results of an exemplary experiment demonstrating that all three donors showed an increase in the early activation marker CD69 on T cells in the presence of CD19DBiTE, but not in the presence of the control DBiTE. [Figure 6]Figures 6A-F include the design, expression and binding of HER2 DNA-encoded monoclonal antibodies (DMAb). Figure 6A shows a schematic of the DNA construct encoding HER2DMAb. Figure 6B shows a Western blot of HER2DMAb or FSHR constructs expressed in 293T cells. Figure 6C shows a Western blot of human IgG from mouse serum electroporated with HER2DMAb or pVax alone 64 days after DNA injection and electroporation (n=5 mice per group). Figure 6D shows the expression levels of human IgG quantified by ELISA from serum of nude mice electroporated with HER2DMAb (n=5 mice per group, 2 independent experiments). Figure 6E shows the binding ELISA of serum from mice expressing HER2DMAb or pVax after coating the plates with human HER2 protein. Figure 6F shows flow cytometry plots showing binding of HER2DMAb to mouse breast cancer cell lines with and without human HER2 expression. [Figure 7]Figures 7A-7F include the in vitro expression and antitumor activity of HER2 DNA-encoded monoclonal antibodies (DMAb). Figure 7A shows the quantified expression levels of HER2DMAb from the supernatants of 293T or RD cells 48 hours after DNA transfection (n=3 / group). Figure 7B shows the in vitro cytotoxicity resulting from the culture of human PBMCs (0.5 million) with OVCAR3-luciferase (10,000) cells in the presence of HER2DMAb or pVax serum or Hu4D5 antibody as a positive control (triplicate). Figure 7C shows the in vitro cytotoxicity resulting from the co-culture of HER2 negative cell line MDA-MD-231 (10,000) cells with human PBMCs (0.5 million) in the presence of HER2DMAb or serum from pVax-injected mice (triplicate). Figure 7D shows the percentage of OVCAR3 cells phagocytosed by macrophages and representative flow cytometry plots in the presence of HER3DMAb, pVax serum, or no added serum (triplicate). Figure 7E shows the in vitro cytotoxicity resulting from co-culture of OVCAR3 (10,000) cells with splenocytes (0.5 million) from Nu / J mice in the presence of serum from HER2DMAb or pVax-injected mice (triplicate). Figure 7F represents mouse anti-HER2DMAb IgG in Nu / J serum at day 0 and day 252 (triplicate). ANOVA. T-test. ***p<0.001. ns: not significant. [Figure 8] Figures 8A-8C include figures showing HER2DMAb binding to HER2 in ovarian cancer. Figure 8A shows HER2 expression in ovarian cancer cell lines OVCAR3, SKOV3, CAOV3, TOV-21G and RNG1 by flow cytometry using anti-HER2 antibody 24D2. Figure 8B shows HER2 expression in serum from mice expressing HER2DMAb. Figure 8C shows immunofluorescence imaging of OVCAR3 tumors stained with serum from HER2DMAb-expressing mice. Scale bar 10 μm. [Figure 9]Figures 9A-9F include figures showing that HER2DMAb blocks HER2 signaling, induces ADCC, and delays cancer progression in vivo. Figure 9A shows a Western blot showing total and phosphorylated Akt and β-actin from OVCAR3 cells treated with the HER2-HER3 agonist HRG in the presence of HER2DMAb or control serum. Figure 9B shows a histogram showing the ADCC assay of HER2DMAb or irrelevant IgG on OVCAR3. Figure 9C shows the growth curve of OVCAR3 tumors implanted in nude mice treated with HER2DMAb or empty vector (two independent experiments with n=5 mice per group). Figure 9D shows the levels of HER2DMAb in the serum of mice bearing OVCAR3 treated with HER2DMAb or empty vector (two independent experiments with n=5 mice per group). Figure 9E shows flow cytometry plots showing expression of HER2 by OVCAR3, Brpkp110, and Brpkp110-hHER2 tumor cells. Figure 9F shows growth curves of Brpkp110-hHER2 tumors implanted in C57Bl / 6 mice treated with HER2DMAb or empty pVax plasmid (representative of two independent experiments with n=5 mice per group). Two-way ANOVA, t-test, log-rank. *p<0.05, ****p<0.001. [Figure 10]Figures 10A-J include figures showing the binding, cytotoxicity, activation, and in vivo efficacy of HER2DBiTE. Figure 10A shows HER2DBiTE binding to recombinant HER2 protein measured by binding ELISA (triplicate). Figure 10B shows HER2DBiTE binding to recombinant CD3 protein measured by binding ELISA (triplicate). Figure 10C shows the number of T cells present in the wells after 24 hours of co-incubation of T cells with OVCAR3 in the presence of HER2DBiTE or pVax serum (triplicate). Figure 10D shows the presence of apoptotic (Annexin V+) cells 5 days after activation of T cells with HER2DBIiTE or pVax serum in the presence of OVCAR3 cells. Anti-CD3 / anti-CD28 beads were used as a positive control (triplicate). Figure 10E shows T cell activation measured as IFNγ in the supernatant of T cells cultured for 24 hours in the presence of HER2DBIiTE or pVax serum and OVCAR3 cells. Anti-CD3 / anti-CD28 beads were used as a positive control and T cells alone were used as a negative control (triplicate). Figure 10F shows T cell activation measured as expression of CD69 in T cells cultured for 72 hours in the presence of HER2DBIiTE or pVax serum and OVCAR3 cells. Anti-CD3 / anti-CD28 beads were used as a positive control and T cells alone were used as a negative control (triplicate). Figure 10G shows T cell activation measured as expression of PD-1 in T cells cultured for 72 hours in the presence of HER2DBIiTE or pVax serum and OVCAR3 cells. Anti-CD3 / anti-CD28 beads were used as a positive control and T cells alone were used as a negative control (triplicate). Figure 10H shows the in vitro cytotoxicity resulting from co-culture of T cells with OVCAR3 cells at different ratios in the presence of serum from HER2DBiTE or pVax mice (two independent experiments in triplicate). FIG. 10I shows mouse anti-HER2DBiTE IgG in Nu / J serum on days 0 and 64 (in triplicate).FIG. 10J shows mean growth curves of OVCAR3 tumors implanted in NSG mice treated with HER2DBiTE, or empty vector without PBMCs and HER2DBiTE with PBMCs, and images of tumors (n=5 mice per group, X indicates no tumor (complete rejection)). T-test, ANOVA, two-way ANOVA. *p<0.05, **p<0.01***p<0.001. ns: not significant. [Figure 11] Figures 11A-11F include figures showing the generation, expression, and antitumor activity of HER2DBiTEs. Figure 11A shows a schematic of the DNA construct encoding HER2DMAb, as well as a cartoon of the BiTE engaging HER2 and TCR. Figure 11B shows a Western blot of human IgG from 1 μl of mouse serum electroporated with HER2DBiTE or pVax empty vector 21 and 28 days after DNA injection and electroporation (n=5 mice per representative group). Figure 11C shows the in vitro cytotoxicity resulting from co-culture of T cells with OVCAR3 cells at different ratios in the presence of serum from HER2DBiTE or pVax mice (two independent experiments in triplicate). Figure 11D shows the in vitro cytotoxicity of serum from mice treated with HER2DBiTE at various time points before and after injection and electroporation of 100 μg at an effector:target ratio of 5:1 using OVCAR3 as the target (triplicate). Figure 11E shows the mean growth curves of OVCAR3 tumors implanted in NSG mice treated with HER2DBiTE or empty vector (n=10 mice per group). Figure 11F shows the individual growth curves of OVCAR3 tumors implanted in NSG mice treated with HER2DBiTE or empty vector (n=10 mice per group). Two-way ANOVA. ***p<0.001. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] The present invention relates to compositions comprising a recombinant nucleic acid sequence encoding a bispecific immune cell engaging antibody (DICE), a recombinant nucleic acid sequence encoding a bispecific T cell engaging (DBiTE) antibody, a fragment thereof, a variant thereof, or a combination thereof, which can be administered to a subject in need thereof to promote in vivo expression and formation of DICE or DBiTE.

[0026] In one embodiment, the DICE or DBiTE comprises at least one antigen binding domain and at least one immune cell engaging domain. In one embodiment, the immune cell engaging domain is specific for an antigen expressed on the surface of an immune cell. The immune cell includes, but is not limited to, T cells, antigen presenting cells, NK cells, neutrophils, and macrophages.

[0027] In various embodiments, the immune cell engaging domain comprises a nucleotide sequence encoding an antibody, fragment thereof, or variant thereof specific for binding to an immune cell specific receptor molecule. In one embodiment, the immune cell specific receptor molecule is a T cell surface antigen. In one embodiment, the T cell specific receptor molecule is one of CD3, TCR, CD28, CD16, NKG2D, Ox40, 4-1BB, CD2, CD5, CD40, FcgR, FceR, FcaR, and CD95.

[0028] In various embodiments, the antigen-binding domain comprises a nucleotide sequence encoding an antibody, fragment thereof, or variant thereof specific for binding to the antigen, in one embodiment, the antibody or fragment thereof is a DNA-encoded monoclonal antibody (DMAb) or a fragment or variant thereof.

[0029] In one embodiment, the antigen-binding domain of DICE or DBiTE is specific for binding to the target antigen and recruiting T cells to the target antigen. In one embodiment, the target antigen is a tumor antigen. In one embodiment, the antigen is CD19, B-cell maturation antigen (BCMA), CD33, fibroblast activation protein (FAP), follicle-stimulating hormone receptor (FSHR), epidermal growth factor receptor (EGFR), prostate-specific membrane antigen (PSMA), CD123, and human epidermal growth factor receptor 2 (Her2). Thus, in one embodiment, the present invention provides compositions comprising one or more DICE or DBiTEs and methods for use in treating or preventing cancer or cancer-related diseases or disorders in a subject.

[0030] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. In case of conflict, the present specification, including definitions, will prevail. Although similar or equivalent methods and materials to those described herein can be used in carrying out or testing the present invention, preferred methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and are not intended to be limiting.

[0031] The terms "comprise(s)", "include(s)", "having", "having", "can", "containing" and variations thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that do not preclude the possibility of additional acts or structures. The singular forms "a", "and", and "the" include plural references unless the context clearly dictates otherwise. The present disclosure also contemplates other embodiments that "comprise", "consist of", and "consist essentially of" the embodiments or elements presented herein, whether or not expressly stated.

[0032] "Antibody" may mean an antibody of class IgG, IgM, IgA, IgD, or IgE, or a fragment, fragment or derivative thereof, including Fab, F(ab')2, Fd, and single chain antibodies, and derivatives thereof. The antibody may be an antibody isolated from a mammalian serum sample, a polyclonal antibody, an affinity purified antibody, or a mixture thereof, which exhibits sufficient binding specificity to the desired epitope or a sequence derived therefrom.

[0033] "Antibody fragment" or "fragment of an antibody", as used interchangeably herein, refers to a portion of an intact antibody that contains an antigen binding site or variable region. The portion does not contain the constant heavy chain domains of the Fc region of the intact antibody (i.e., CH2, CH3, or CH4, depending on the antibody isotype). Examples of antibody fragments include, but are not limited to, Fab fragments, Fab' fragments, Fab'-SH fragments, F(ab')2 fragments, Fd fragments, Fv fragments, diabodies, single-chain Fv (scFv) molecules, single-chain polypeptides containing only one light chain variable domain, single-chain polypeptides containing three CDRs of a light chain variable domain, single-chain polypeptides containing only one heavy chain variable region, and single-chain polypeptides containing three CDRs of a heavy chain variable region.

[0034] "Antigen" refers to a protein that has the ability to generate an immune response in a host. An antigen can be recognized and bound by an antibody. An antigen can originate from within the body or from the external environment.

[0035] As used herein, "coding sequence" or "encoding nucleic acid" may be meant to refer to a nucleic acid (RNA or DNA molecule) that comprises a nucleotide sequence that encodes an antibody, as described herein. The coding sequence may further comprise initiation and termination signals operably linked to control elements including a promoter, and a polyadenylation signal capable of directing expression in cells of an individual or mammal to which the nucleic acid is administered. The coding sequence may further comprise a sequence that encodes a signal peptide.

[0036] As used herein, "complement" or "complementary" means that a nucleic acid can refer to Watson-Crick (e.g., AT / U and CG) or Hoogsteen base pairing between nucleotides or nucleotide analogs of a nucleic acid molecule.

[0037] "Constant current" as used herein defines the current that a tissue, or cells defining the tissue, undergoes or experiences over the period of time that an electrical pulse is delivered to the tissue. The electrical pulse is delivered from an electroporation device as described herein. The electroporation device provided herein preferably has a feedback element with immediate feedback, so that the current remains at a constant amperage in the tissue over the life of the electrical pulse. The feedback element measures the resistance of the tissue (or cells) throughout the duration of the pulse and can cause the electroporation device to change its electrical energy output (e.g., increase the voltage), so that the current in the same tissue remains constant throughout and between electrical pulses (on the order of microseconds). In some embodiments, the feedback element includes a controller.

[0038] As used herein, "current feedback" or "feedback" may be used interchangeably and may refer to the activity response of the provided electroporation device, which includes measuring the current in the tissue between the electrodes and modifying the energy output delivered by the EP device accordingly to maintain the current at a constant level. This constant level is preset by the user before the start of the pulse sequence or electrical treatment. The feedback may be achieved by the electroporation component of the electroporation device, for example, a controller, such that an electrical circuit therein continuously monitors the current in the tissue between the electrodes, compares the monitored current (or the current in the tissue) with a preset current, and continuously makes energy output adjustments to maintain the monitored current at a preset level. The feedback loop may be immediate, since it is an analog closed-loop feedback.

[0039] As used herein, "distributed current" may refer to a pattern of current delivered from the various needle electrode arrays of the electroporation devices described herein, which pattern minimizes, or preferably eliminates, the occurrence of electroporation-associated thermal stress on any region of the tissue being electroporated.

[0040] "Electroporation," "electropermeabilization," or "electrokinetic enhancement" ("EP"), as used interchangeably herein, may refer to the use of transmembrane electric field pulses to induce microscopic pathways (pores) in biological membranes, the presence of which allows biomolecules such as plasmids, oligonucleotides, siRNA, drugs, ions, and water to pass from one side of the cell membrane to the other.

[0041] As used herein, "endogenous antibodies" may refer to antibodies produced in a subject to which an effective dose of an antigen is administered for the induction of a humoral immune response.

[0042] As used herein, a "feedback mechanism" may refer to a process implemented by either software or hardware (firmware) that receives the desired tissue impedance (before, during, and / or after the delivery of a pulse of energy), compares it to a current value, preferably the current, and adjusts the pulse of energy delivered to achieve a pre-set value. The feedback mechanism may be implemented by an analog closed loop circuit.

[0043] "Fragment" may refer to a polypeptide fragment of an antibody that is functional, i.e., capable of binding to a desired target and having the same intended effect as the full-length antibody. An antibody fragment may be 100% identical to the full-length, except for the deletion of at least one amino acid from the N-terminus and / or C-terminus, in each case with or without the presence of a signal peptide and / or methionine at position 1. A fragment may comprise a percent of 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more of the length of a particular full-length antibody, excluding any added heterologous signal peptide. A fragment may include a fragment of a polypeptide that is 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more identical to an antibody, and may additionally include an N-terminal methionine or a heterologous signal peptide that is not included when calculating percent identity. A fragment may further include an N-terminal methionine and / or a signal peptide, such as an immunoglobulin signal peptide, e.g., an IgE or IgG signal peptide. The N-terminal methionine and / or signal peptide may be linked to a fragment of an antibody.

[0044] Fragments of a nucleic acid sequence encoding an antibody can be 100% identical to the full length, except for lacking at least one nucleotide from the 5' and / or 3' end, in each case with or without the presence of sequences encoding a signal peptide and / or a methionine at position 1. Fragments can comprise a percentage of 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more of the length of the particular full length coding sequence, excluding any added heterologous signal peptide. Fragments may include fragments that encode a polypeptide that is 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more identical to the antibody, and may, in addition, optionally include sequences encoding an N-terminal methionine or a heterologous signal peptide that are not included when calculating percent identity. Fragments may further include a coding sequence for an N-terminal methionine and / or a signal peptide, such as an immunoglobulin signal peptide, e.g., an IgE or IgG signal peptide. A coding sequence encoding an N-terminal methionine and / or a signal peptide may be linked to a fragment of the coding sequence.

[0045] As used herein, "genetic construct" refers to a DNA or RNA molecule that contains a nucleotide sequence that codes for a protein, such as an antibody. The coding sequence includes a start and stop signal that is operably linked to a regulatory element that includes a promoter and a polyadenylation signal that can induce expression in the cells of an individual to which the nucleic acid molecule is administered. As used herein, the term "expressible form" refers to a genetic construct that includes the necessary control elements operably linked to a coding sequence that codes for a protein, so that the coding sequence is expressed when present in the cells of an individual.

[0046] "Identical" or "identity" as used herein in the context of two or more nucleic acid or polypeptide sequences may mean that the sequences have a specified percentage of residues that are the same over a specified region. The percentage can be calculated by optimally aligning the two sequences, comparing the two sequences in a specified region, determining the number of positions where identical residues occur in both sequences to calculate the number of matching positions, dividing the number of matching positions by the total number of positions in the specified region, and multiplying the result by 100 to obtain the percentage of sequence identity. If the two sequences are of different length or the alignment produces one or more sticky ends and only a single sequence is included in the specified comparison region, the residues of the single sequence are included in the denominator but not in the numerator of the calculation. When comparing DNA and RNA, thymine (T) and uracil (U) may be considered equivalent. Identity can be performed manually or by using a computer sequence algorithm such as BLAST or BLAST 2.0.

[0047] As used herein, "impedance" may be used when discussing feedback mechanisms and can be converted to a current value according to Ohm's law, thus allowing comparison to a preset current.

[0048] As used herein, "immune response" may refer to activation of a host's immune system, e.g., a mammal's immune system, in response to the introduction of one or more nucleic acids and / or peptides. The immune response may be in the form of a cellular or humoral response, or both.

[0049] As used herein, "nucleic acid" or "oligonucleotide" or "polynucleotide" may refer to at least two nucleotides covalently linked together. The depiction of a single strand also defines the sequence of the complementary strand. Thus, a nucleic acid also encompasses the complementary strand of the depicted single strand. Many variants of a nucleic acid can be used for the same purpose as a given nucleic acid. Thus, a nucleic acid also encompasses substantially identical nucleic acids and their complements. A single strand provides a probe that can hybridize to a target sequence under stringent hybridization conditions. Thus, a nucleic acid also encompasses a probe that hybridizes under stringent hybridization conditions.

[0050] Nucleic acids may be single-stranded or double-stranded, or may contain portions of both double-stranded and single-stranded sequences. Nucleic acids may be DNA, both genomic and cDNA, RNA, or hybrids, and may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine, hypoxanthine, isocytosine, and isoguanine. Nucleic acids may be obtained by chemical synthesis methods or by recombinant methods.

[0051] As used herein, "operably linked" may mean that the expression of a gene is under the control of a promoter with which it is spatially connected. The promoter may be located 5' (upstream) or 3' (downstream) of the gene under its control. The distance between the promoter and the gene may be approximately the same as the distance between the promoter and the gene that it controls in the gene from which the promoter is derived. As is known in the art, variations in this distance may be accommodated without loss of promoter function.

[0052] As used herein, "peptide," "protein," or "polypeptide" can refer to a linked sequence of amino acids, which can be natural, synthetic, or a modified or combination of natural and synthetic.

[0053] As used herein, a "promoter" may refer to a synthetic or naturally derived molecule that can confer, activate, or enhance expression of a nucleic acid in a cell. A promoter may contain one or more specific transcription control sequences to further enhance its expression and / or to alter spatial and / or temporal expression. A promoter may also contain distal enhancer or repressor elements, which may be located as many as several thousand base pairs from the start site of transcription. Promoters may be derived from sources including viruses, bacteria, fungi, plants, insects, and animals. A promoter may control the expression of a genetic component constitutively, or differentially for the cell, tissue or organ in which expression occurs, or for the developmental stage in which expression occurs, or in response to an external stimulus such as physiological stress, a pathogen, a metal ion, or an inducer. Representative examples of promoters include the bacteriophage T7 promoter, the bacteriophage T3 promoter, the SP6 promoter, the lac operator-promoter, the tac promoter, the SV40 late promoter, the SV40 early promoter, the RSV-LTR promoter, the CMV IE promoter, the SV40 early promoter or the SV40 late promoter, and the CMV IE promoter.

[0054] "Signal peptide" and "leader sequence" are used interchangeably herein and refer to an amino acid sequence that can be linked at the amino terminus of a protein described herein. A signal peptide / leader sequence typically directs the localization of a protein. A signal peptide / leader sequence as used herein preferably facilitates secretion of a protein from the cell in which it is produced. A signal peptide / leader sequence is often cleaved from the remainder of a protein, and is often referred to as a mature protein after secretion from a cell. A signal peptide / leader sequence is linked at the N-terminus of a protein.

[0055] As used herein, "stringent hybridization conditions" may refer to the average conditions under which a first nucleic acid sequence (e.g., a probe) will hybridize to a second nucleic acid sequence (e.g., a target) as in a complex mixture of nucleic acids. Stringent conditions are sequence-dependent and will be different in different circumstances. Stringent conditions are determined by the thermal melting point (T) for a particular sequence at a defined ionic strength pH. m ) can be selected to be about 5 to 10°C lower than T m can be the temperature (under defined ionic strength, pH, and nucleic acid concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (because the target sequences are present in excess, T m (At equilibrium, 50% of the probes are occupied). Stringent conditions can be those in which the salt concentration is less than about 1.0 M sodium ion, such as about 0.01-1.0 M sodium ion concentration (or other salt) at pH 7.0-8.3, and the temperature is at least about 30° C. for short probes (e.g., about 10-50 nucleotides) and at least about 60° C. for long probes (e.g., more than about 50 nucleotides). Stringent conditions can also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal can be at least 2-10 times background hybridization. Exemplary stringent hybridization conditions include: 50% formamide, 5×SSC, and 1% SDS, incubated at 42° C., or 5×SSC, 1% SDS, incubated at 65° C., washed in 0.2×SSC and 0.1% SDS at 65° C.

[0056] As used herein, "subject" and "patient" refer interchangeably to any vertebrate, including, but not limited to, mammals (e.g., cows, pigs, camels, llamas, horses, goats, rabbits, sheep, hamsters, guinea pigs, cats, dogs, rats, and mice, non-human primates (e.g., monkeys such as cynomolgus or rhesus monkeys, chimpanzees, etc.), and humans). In some embodiments, the subject may be human or non-human. The subject or patient may be undergoing other forms of therapy.

[0057] As used herein, "substantially complementary" means that a first sequence is complementary to a second sequence over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, or more nucleotides or amino acids. It can mean that the sequence is at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence, or that the two sequences hybridize under stringent hybridization conditions.

[0058] As used herein, "substantially identical" means that the first and second sequences are 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 300, 400, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9 ... "over a region of 00, 500, 600, 700, 800, 900, 1000, 1100 or more nucleotides or amino acids, or with respect to a nucleic acid, can mean at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

[0059] As used herein, "synthetic antibody" refers to an antibody encoded by a recombinant nucleic acid sequence described herein and generated in a subject.

[0060] As used herein, "treatment" or "treating" may refer to the protection of a subject from a disease through means of preventing, inhibiting, suppressing, or completely eliminating the disease. Preventing a disease involves administering an antibody of the invention to a subject prior to the onset of the disease. Suppressing a disease involves administering an antibody of the invention to a subject after induction of the disease but prior to its clinical appearance. Suppressing a disease involves administering an antibody of the invention to a subject after the clinical appearance of the disease.

[0061] "Variant," as used herein with respect to a nucleic acid, may mean (i) a portion or fragment of a referenced nucleotide sequence, (ii) the complement of the referenced nucleotide sequence or a portion thereof, (iii) a nucleic acid that is substantially identical to the referenced nucleic acid or its complement, or (iv) a nucleic acid that hybridizes under stringent conditions to the referenced nucleic acid, its complement, or a sequence substantially identical thereto.

[0062] A "variant" for a peptide or polypeptide whose amino acid sequence differs by an amino acid insertion, deletion, or conservative substitution retains at least one biological activity. A variant can also refer to a protein having an amino acid sequence that is substantially identical to a reference protein having an amino acid sequence that retains at least one biological activity. Conservative substitutions of amino acids, i.e., replacing an amino acid with an amino acid that differs in similar properties (e.g., hydrophilicity, degree and distribution of charged regions), are recognized in the art as typically involving minor changes. These minor changes can be identified, in part, by considering the hydropathic index of an amino acid, as understood in the art. Kyte et al., J. Mol. Biol. 157:105-132 (1982). The hydropathic index of an amino acid is based on consideration of its hydrophobicity and charge. It is known in the art that amino acids of similar hydropathic indexes can be substituted and still retain protein function. In one embodiment, amino acids with a hydropathic index of ±2 are substituted. The hydrophilicity of an amino acid can also be used to identify substitutions that will result in a protein that retains biological function. Consideration of the hydrophilicity of an amino acid in the context of a peptide allows for the calculation of the greatest local average hydrophilicity of the peptide, a useful measure that has been reported to correlate well with antigenicity and immunogenicity. U.S. Patent No. 4,554,101 is incorporated herein by reference in its entirety. Substitution of amino acids with similar hydrophilicity values ​​can result in peptides that retain biological activity, e.g., immunogenicity, as understood in the art. Substitutions can be made with amino acids that have hydrophilicity values ​​within ±2 of each other. Both the hydrophobicity index and hydrophilicity value of an amino acid are influenced by the particular side chain of that amino acid. Consistent with that observation, it is understood that amino acid substitutions that are compatible with biological function depend on the relative similarity of the amino acids, and in particular the side chains of those amino acids, as revealed by hydrophobicity, hydrophilicity, charge, size, and other properties.

[0063] A variant may be a nucleic acid sequence that is substantially identical over the full length of a complete gene sequence or a fragment thereof. The nucleic acid sequence may be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the full length of a gene sequence or a fragment thereof. A variant may be an amino acid sequence that is substantially identical over the full length of an amino acid sequence or a fragment thereof. The amino acid sequence may be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the full length of an amino acid sequence or a fragment thereof.

[0064] "Vector" as used herein may refer to a nucleic acid sequence that includes a replication origin. A vector may be a plasmid, a bacteriophage, a bacterial artificial chromosome, or a yeast artificial chromosome. A vector may be a DNA or an RNA vector. A vector may be either a self-replicating extrachromosomal vector or a vector that integrates into a host genome.

[0065] For the recitation of numerical ranges herein, each intervening number is expressly contemplated with the same precision. For example, for the range 6 to 9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0 to 7.0, the numbers 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are expressly contemplated.

[0066] composition In one embodiment, the present invention relates to a composition comprising a recombinant nucleic acid sequence encoding DICE or DBiTE, a fragment thereof, a variant thereof, or a combination thereof, which, when administered to a subject in need thereof, can result in the production of the synthetic DNA-encoded bispecific immune cell engager in the subject.

[0067] In one embodiment, the DICE or DBiTE comprises at least one antigen binding domain and at least one immune cell engaging domain. In one embodiment, the immune cell engaging domain is specific for an antigen expressed on the surface of an immune cell. The immune cell includes, but is not limited to, T cells, antigen presenting cells, NK cells, neutrophils, and macrophages.

[0068] In various embodiments, the immune cell engaging domain comprises a nucleotide sequence encoding an antibody, fragment thereof, or variant thereof specific for binding to an immune cell specific receptor molecule. In one embodiment, the immune cell specific receptor molecule is a T cell surface antigen. In one embodiment, the T cell specific receptor molecule is one of CD3, TCR, CD28, CD16, NKG2D, Ox40, 4-1BB, CD2, CD5, CD40, FcgR, FceR, FcaR, and CD95.

[0069] In various embodiments, the antigen-binding domain comprises an antibody, fragment thereof, or variant thereof that is specific for binding to the antigen.In one embodiment, the antigen is a tumor antigen.In one embodiment, the antigen is CD19, B-cell maturation antigen (BCMA), CD33, fibroblast activation protein (FAP), follicle-stimulating hormone receptor (FSHR), epidermal growth factor receptor (EGFR), prostate-specific membrane antigen (PSMA), CD123, or human epidermal growth factor receptor 2 (Her2).

[0070] In one embodiment, the nucleotide sequence encoding a CD19DBiTE encodes the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6, or a fragment or variant thereof. In one embodiment, the nucleotide sequence encoding a CD19DBiTE comprises the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5, or a fragment or variant thereof.

[0071] In one embodiment, the nucleotide sequence encoding a BCMADBiTE encodes the amino acid sequence of SEQ ID NO:8, SEQ ID NO:10, or SEQ ID NO:12, or a fragment or variant thereof. In one embodiment, the nucleotide sequence encoding a BCMADBiTE comprises the nucleotide sequence of SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO:11, or a fragment or variant thereof.

[0072] In one embodiment, the nucleotide sequence encoding CD33DBiTE encodes the amino acid sequence of SEQ ID NO: 14, SEQ ID NO: 16, or SEQ ID NO: 18, or a fragment or variant thereof. In one embodiment, the nucleotide sequence encoding CD33DBiTE comprises the nucleotide sequence of SEQ ID NO: 13, SEQ ID NO: 15, or SEQ ID NO: 17, or a fragment or variant thereof.

[0073] In one embodiment, the nucleotide sequence encoding a FAPBiTE encodes the amino acid sequence of SEQ ID NO:20, SEQ ID NO:22, or SEQ ID NO:24, or a fragment or variant thereof. In one embodiment, the nucleotide sequence encoding a FAPDBiTE comprises the nucleotide sequence of SEQ ID NO:19, SEQ ID NO:21, or SEQ ID NO:23, or a fragment or variant thereof.

[0074] In one embodiment, the nucleotide sequence encoding the FSHRDBiTE encodes the amino acid sequence of SEQ ID NO:26, SEQ ID NO:28, or SEQ ID NO:30, or a fragment or variant thereof. In one embodiment, the nucleotide sequence encoding the FSHRDBiTE comprises the nucleotide sequence of SEQ ID NO:25, SEQ ID NO:27, or SEQ ID NO:29, or a fragment or variant thereof.

[0075] In one embodiment, the nucleotide sequence encoding an EGFRDBiTE encodes the amino acid sequence of SEQ ID NO: 32, SEQ ID NO: 34, or SEQ ID NO: 36, or a fragment or variant thereof. In one embodiment, the nucleotide sequence encoding an EGFRDBiTE comprises the nucleotide sequence of SEQ ID NO: 31, SEQ ID NO: 33, or SEQ ID NO: 35, or a fragment or variant thereof.

[0076] In one embodiment, a nucleotide sequence encoding a PSMADBiTE encodes the amino acid sequence of SEQ ID NO: 38, SEQ ID NO: 40, or SEQ ID NO: 42, or a fragment or variant thereof. In one embodiment, a nucleotide sequence encoding a PSMADBiTE comprises the nucleotide sequence of SEQ ID NO: 37, SEQ ID NO: 41, or SEQ ID NO: 43, or a fragment or variant thereof.

[0077] In one embodiment, the nucleotide sequence encoding CD123DBiTE encodes the amino acid sequence of SEQ ID NO: 44, SEQ ID NO: 46, or SEQ ID NO: 48, or a fragment or variant thereof. In one embodiment, the nucleotide sequence encoding CD123DBiTE comprises the nucleotide sequence of SEQ ID NO: 43, SEQ ID NO: 45, or SEQ ID NO: 47, or a fragment or variant thereof.

[0078] In one embodiment, the nucleotide sequence encoding a HER2DBiTE encodes the amino acid sequence of SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:58, or SEQ ID NO:60, or a fragment or variant thereof. In one embodiment, the nucleotide sequence encoding a HER2DBiTE comprises the nucleotide sequence of SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, or SEQ ID NO:67, or a fragment or variant thereof.

[0079] In one embodiment, the nucleotide sequence encoding EGFRvIII2DICE encodes the amino acid sequence of SEQ ID NO: 70 or SEQ ID NO: 72, or a fragment or variant thereof. In one embodiment, the nucleotide sequence encoding EGFRvIII2DICE comprises the nucleotide sequence of SEQ ID NO: 69 or SEQ ID NO: 71, or a fragment or variant thereof.

[0080] In one embodiment, the nucleotide sequence encoding HER2DICE encodes the amino acid sequence of SEQ ID NO: 74, or SEQ ID NO: 76, or a fragment or variant thereof. In one embodiment, the nucleotide sequence encoding HER2DICE comprises the nucleotide sequence of SEQ ID NO: 73 or SEQ ID NO: 75, or a fragment or variant thereof.

[0081] In one embodiment, the composition comprises a nucleotide sequence encoding an anti-Her2 antibody (HER2DMAb). In one embodiment, the nucleotide sequence encoding the HER2DMAb comprises a nucleotide sequence encoding SEQ ID NO:62, SEQ ID NO:64, or a fragment or variant thereof. In one embodiment, the nucleotide sequence encoding the HER2DMAb comprises SEQ ID NO:61, SEQ ID NO:63, or a fragment or variant thereof.

[0082] In one embodiment, the composition comprises an scFv anti-Her2 antibody. In one embodiment, the nucleotide sequence encoding the scFv anti-Her2 antibody comprises a nucleotide sequence encoding SEQ ID NO: 66, or a fragment or variant thereof. In one embodiment, the nucleotide sequence encoding the scFv anti-Her2 antibody comprises SEQ ID NO: 65, or a fragment or variant thereof. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4]

[0083] In certain embodiments, the compositions may treat, prevent, and / or protect against a disease or disorder associated with the antigen to which the synthetic antibody of the invention (e.g., DMAb, ScFv antibody fragment, DICE, or DBiTE) binds. In one embodiment, the compositions of the invention may treat, prevent, and / or protect against any disease, disorder, or condition associated with expression of a target antigen. In certain embodiments, the compositions may treat, prevent, and / or protect against cancer.

[0084] The synthetic antibody (e.g., DMAb, ScFv antibody fragment, DICE or DBiTE) may treat, prevent and / or protect against disease in a subject to which the composition is administered. The synthetic antibody (e.g., DMAb, ScFv antibody fragment, DICE or DBiTE) may promote disease survival in a subject to which the composition is administered. The synthetic antibody (e.g., DMAb, ScFv antibody fragment, DICE or DBiTE) may provide at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% disease survival in a subject to which the composition is administered. In other embodiments, the synthetic antibody (e.g., DMAb, ScFv antibody fragment, DICE or DBiTE) can provide at least about 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80% survival from the disease in a subject administered the composition.

[0085] The composition may result in the generation of a synthetic antibody (e.g., DMAb, ScFv antibody fragment, DICE or DBiTE) in the subject within at least about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 20 hours, 25 hours, 30 hours, 35 hours, 40 hours, 45 hours, 50 hours, or 60 hours of administration of the composition to the subject. The composition may result in the generation of a synthetic antibody (e.g., DMAb, ScFv antibody fragment, DICE or DBiTE) in the subject within at least about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, or 10 days of administration of the composition to the subject. The composition may result in production of a synthetic antibody (e.g., DMAb, ScFv antibody fragment, DICE or DBiTE) in the subject within about 1 hour to about 6 days, about 1 hour to about 5 days, about 1 hour to about 4 days, about 1 hour to about 3 days, about 1 hour to about 2 days, about 1 hour to about 1 day, about 1 hour to about 72 hours, about 1 hour to about 60 hours, about 1 hour to about 48 hours, about 1 hour to about 36 hours, about 1 hour to about 24 hours, about 1 hour to about 12 hours, or about 1 hour to about 6 hours of administration of the composition to the subject.

[0086] The composition, when administered to a subject in need thereof, may result in the production of a synthetic antibody (e.g., a DMAb, an ScFv antibody fragment, a DICE, or a DBiTE) in the subject more rapidly than the production of endogenous antibodies in the subject administered the antigen to induce a humoral immune response. The composition may result in the production of a synthetic antibody (e.g., a DMAb, an ScFv antibody fragment, a DICE, or a DBiTE) at least about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, or 10 days prior to the production of endogenous antibodies in the subject administered the antigen to induce a humoral immune response.

[0087] The compositions of the present invention may have the characteristics necessary for an effective composition, such as being safe so that the composition does not cause illness or death, being protective against illness, as well as providing ease of administration, few side effects, biological stability, and low cost per dose.

[0088] Recombinant Nucleic Acid Sequences As described above, the composition may include a recombinant nucleic acid sequence. The recombinant nucleic acid sequence may encode a synthetic antibody (e.g., a DMAb, an ScFv antibody fragment, a DICE or a DBiTE), a fragment thereof, a variant thereof, or a combination thereof. Antibodies are described in more detail below.

[0089] A recombinant nucleic acid sequence may be a heterologous nucleic acid sequence. A recombinant nucleic acid sequence may contain at least one heterologous nucleic acid sequence or one or more heterologous nucleic acid sequences.

[0090] The recombinant nucleic acid sequence may be an optimized nucleic acid sequence. Such optimization may increase or change the immunogenicity of the antibody. Optimization may also improve transcription and / or translation. Optimization may include one or more of the following: low GC content leader sequence to increase transcription, mRNA stability and codon optimization, addition of a Kozak sequence (e.g., GCCACC) for increased translation, addition of an immunoglobulin (Ig) leader sequence that codes for a signal peptide, and elimination of cis-acting sequence motifs (i.e., internal TATA boxes) wherever possible.

[0091] A recombinant nucleic acid sequence may comprise one or more recombinant nucleic acid sequence constructs. A recombinant nucleic acid sequence construct may comprise one or more components described in more detail below.

[0092] The recombinant nucleic acid sequence construct may include a heterologous nucleic acid sequence encoding a heavy chain polypeptide, a fragment thereof, a variant thereof, or a combination thereof. The recombinant nucleic acid sequence construct may include a heterologous nucleic acid sequence encoding a light chain polypeptide, a fragment thereof, a variant thereof, or a combination thereof. The recombinant nucleic acid sequence construct may also include a heterologous nucleic acid sequence encoding a protease or peptidase cleavage site. The recombinant nucleic acid sequence construct may also include a heterologous nucleic acid sequence encoding an internal ribosome entry site (IRES). The IRES may be either a viral IRES or a eukaryotic IRES. The recombinant nucleic acid sequence construct may include one or more leader sequences, each of which encodes a signal peptide. The recombinant nucleic acid sequence construct may include one or more promoters, one or more introns, one or more transcription termination regions, one or more start codons, one or more termination or stop codons, and / or one or more polyadenylation signals. The recombinant nucleic acid sequence construct may also include one or more linker or tag sequences. The tag sequence may encode a hemagglutinin (HA) tag.

[0093] Heavy Chain Polypeptide The recombinant nucleic acid sequence construct may comprise a heterologous nucleic acid encoding a heavy chain polypeptide, a fragment thereof, a variant thereof, or a combination thereof. The heavy chain polypeptide may comprise a variable heavy chain (VH) region and / or at least one constant heavy chain (CH) region. The at least one constant heavy chain region may comprise constant heavy chain region 1 (CH1), constant heavy chain region 2 (CH2), and constant heavy chain region 3 (CH3), and / or a hinge region.

[0094] In some embodiments, the heavy chain polypeptide may comprise a VH region and a CH1 region. In other embodiments, the heavy chain polypeptide may comprise a VH region, a CH1 region, a hinge region, a CH2 region, and a CH3 region.

[0095] A heavy chain polypeptide may comprise a set of complementarity determining regions ("CDRs"). A CDR set may comprise three hypervariable regions of the VH region. Proceeding from the N-terminus of the heavy chain polypeptide, these CDRs are designated as "CDR1", "CDR2" and "CDR3", respectively. CDR1, CDR2 and CDR3 of the heavy chain polypeptide may contribute to antigen binding or recognition.

[0096] Light Chain Polypeptide The recombinant nucleic acid sequence construct may include a heterologous nucleic acid sequence encoding a light chain polypeptide, a fragment thereof, a variant thereof, or a combination thereof. The light chain polypeptide may include a variable light (VL) region and / or a constant light (CL) region.

[0097] The light chain polypeptide may comprise a set of complementarity determining regions ("CDRs"). The CDR set may comprise three hypervariable regions of the VL region. Proceeding from the N-terminus of the light chain polypeptide, these CDRs are designated as "CDR1", "CDR2" and "CDR3", respectively. The CDR1, CDR2 and CDR3 of the light chain polypeptide may contribute to antigen binding or recognition.

[0098] Protease cleavage site The recombinant nucleic acid sequence construct may include a heterologous nucleic acid sequence that encodes a protease cleavage site. The protease cleavage site may be recognized by a protease or peptidase. The protease may be an endopeptidase or an endoprotease, such as, but not limited to, furin, elastase, HtrA, calpain, trypsin, chymotrypsin, trypsin, and pepsin. The protease may be furin. In other embodiments, the protease may be a serine protease, a threonine protease, a cysteine ​​protease, an aspartic acid protease, a metalloprotease, a glutamic acid protease, or any protease that cleaves internal peptide bonds (i.e., does not cleave N- or C-terminal peptide bonds).

[0099] The protease cleavage site may include one or more amino acid sequences that facilitate or increase the efficiency of cleavage. The one or more amino acid sequences may facilitate or increase the efficiency of forming or generating a separate polypeptide. The one or more amino acid sequences may include a 2A peptide sequence.

[0100] Linker sequence The recombinant nucleic acid sequence construct may include one or more linker sequences. The linker sequence may spatially separate or link one or more components described herein. In other embodiments, the linker sequence may code for an amino acid sequence that spatially separates or links two or more polypeptides. In one embodiment, the linker sequence is a G4S linker sequence having the amino acid sequence of GGGGSGGGSGGGGS (SEQ ID NO: 68).

[0101] promoter Recombinant nucleic acid sequence constructs may contain one or more promoters. One or more promoters may be any promoter that can drive and regulate gene expression. Such promoters are cis-acting sequence elements required for DNA-dependent RNA polymerase-mediated transcription. The choice of promoter used to induce gene expression depends on the specific application. Promoter may be located at approximately the same distance from transcription start in recombinant nucleic acid sequence constructs as it is from the transcription start site in its natural setting. However, variations in this distance may be accommodated without loss of promoter function.

[0102] The promoter may be operably linked to the heterologous nucleic acid sequence encoding the heavy and / or light chain polypeptide. The promoter may be a promoter shown to be effective for expression in eukaryotic cells. The promoter operably linked to the coding sequence may be a promoter derived from Simian Virus 40 (SV40), such as the CMV promoter, the SV40 early promoter and the SV40 late promoter, a mouse mammary tumor virus (MMTV) promoter, a human immunodeficiency virus (HIV) promoter, such as the bovine immunodeficiency virus (BIV) long terminal repeat (LTR) promoter, a Moloney virus promoter, an avian leukosis virus (ALV) promoter, a cytomegalovirus (CMV) promoter, such as the CMV immediate early promoter, an Epstein-Barr virus (EBV) promoter, or a Rous sarcoma virus (RSV) promoter. The promoter may also be a promoter derived from a human gene, such as human actin, human myosin, human hemoglobin, human muscle creatine, human polyhedrin, or human metallothionein.

[0103] The promoter may be a constitutive promoter or an inducible promoter that starts transcription only when the host cell is exposed to some specific external stimulus. In the case of a multicellular organism, the promoter may also be specific to a particular tissue or organ or development stage. The promoter may also be a tissue-specific promoter, such as a natural or synthetic muscle or skin specific promoter. Examples of such promoters are described in U.S. Patent Application Publication No. 2004 / 0175727, the contents of which are incorporated herein in their entirety.

[0104] The promoter can be associated with an enhancer. The enhancer can be located upstream of the coding sequence. The enhancer can be human actin, human myosin, human hemoglobin, human muscle creatine, or a viral enhancer such as one from CMV, FMDV, RSV, or EBV. Polynucleotide function enhancement is described in U.S. Patent Nos. 5,593,972, 5,962,428, and WO94 / 016737, the contents of each of which are fully incorporated by reference.

[0105] Transcription termination region The recombinant nucleic acid sequence construct may contain one or more transcription termination regions. The transcription termination region may be downstream of the coding sequence to provide efficient termination. The transcription termination region may be obtained from the same gene as the promoter described above, or may be obtained from one or more different genes.

[0106] Start codon The recombinant nucleic acid sequence construct may include one or more initiation codons. The initiation codon may be located upstream of the coding sequence. The initiation codon may be in frame with the coding sequence. The initiation codon may be associated with one or more signals required for efficient translation initiation, such as, but not limited to, a ribosome binding site.

[0107] Stop codon A recombinant nucleic acid sequence construct may contain one or more termination or stop codons. The termination codon may be downstream of the coding sequence. The termination codon may be in frame with the coding sequence. The termination codon may be associated with one or more signals required for efficient translation termination.

[0108] Polyadenylation Signal The recombinant nucleic acid sequence construct may include one or more polyadenylation signals. The polyadenylation signal may include one or more signals required for efficient polyadenylation of the transcript. The polyadenylation signal may be located downstream of the coding sequence. The polyadenylation signal may be an SV40 polyadenylation signal, an LTR polyadenylation signal, a bovine growth hormone (bGH) polyadenylation signal, a human growth hormone (hGH) polyadenylation signal, or a human β-globin polyadenylation signal. The SV40 polyadenylation signal may be a polyadenylation signal from pCEP4 plasmid (Invitrogen, San Diego, CA).

[0109] Leader sequence The recombinant nucleic acid sequence construct may include one or more leader sequences. The leader sequence may encode a signal peptide. The signal peptide may be an immunoglobulin (Ig) signal peptide, such as, but not limited to, an IgG signal peptide and an IgE signal peptide.

[0110] Expression from recombinant nucleic acid sequence constructs As described above, the recombinant nucleic acid sequence construct may include, among one or more components, a heterologous nucleic acid sequence encoding a heavy chain polypeptide and / or a heterologous nucleic acid sequence encoding a light chain polypeptide. Thus, the recombinant nucleic acid sequence construct may facilitate expression of a heavy chain polypeptide and / or a light chain polypeptide.

[0111] When configuration 1 as described above is utilized, the first recombinant nucleic acid sequence construct can facilitate expression of a heavy chain polypeptide and the second recombinant nucleic acid sequence construct can facilitate expression of a light chain polypeptide. When configuration 2 as described above is utilized, the recombinant nucleic acid sequence construct can facilitate expression of a heavy chain polypeptide and a light chain polypeptide.

[0112] Upon expression, for example, but not limited to, in a cell, organism, or mammal, the heavy and light chain polypeptides can assemble into a composite antibody (e.g., DMAb, ScFv antibody fragment, DICE, or DBiTE). In particular, the heavy and light chain polypeptides can interact with each other such that the assembly results in a composite antibody (e.g., DMAb, ScFv antibody fragment, DICE, or DBiTE) that can bind to an antigen. In other embodiments, the heavy and light chain polypeptides can interact with each other such that the assembly results in a composite antibody (e.g., DMAb, ScFv antibody fragment, DICE, or DBiTE) that is more immunogenic compared to an antibody that is not assembled as described herein. In yet other embodiments, the heavy and light chain polypeptides can interact with each other such that the assembly results in a composite antibody (e.g., DMAb, ScFv antibody fragment, DICE, or DBiTE) that can induce or induce an immune response against an antigen.

[0113] vector The recombinant nucleic acid sequence construct described above can be placed in one or more vectors.One or more vectors can contain a replication origin.One or more vectors can be plasmid, bacteriophage, bacterial artificial chromosome, or yeast artificial chromosome.One or more vectors can be either self-replicating extrachromosomal vector or vector that integrates into host genome.

[0114] One or more vectors can be heterologous expression constructs, which are generally plasmids used to introduce specific genes into target cells.When expression vectors enter cells, the heavy and / or light chain polypeptides encoded by recombinant nucleic acid sequence constructs are produced by cell transcription and translation machinery ribosome complexes.One or more vectors can express large amounts of stable messenger RNA, and thus proteins.

[0115] Expression vector The one or more vectors can be circular plasmids or linear nucleic acids.Circular plasmids and linear nucleic acids can induce the expression of specific nucleotide sequences in suitable target cells.The one or more vectors that contain recombinant nucleic acid sequence constructs can be chimeric, meaning that at least one of its components is heterologous to at least one of its other components.

[0116] Plasmids One or more vectors can be plasmids.Plasmids can be useful for transfecting cells with recombinant nucleic acid sequence constructs.Plasmids can be useful for introducing recombinant nucleic acid sequence constructs into subjects.Plasmids can also contain control sequences that can be adequate for gene expression in the cells that the plasmid is administered to.

[0117] The plasmid may also contain a mammalian origin of replication to maintain the plasmid extrachromosomally and produce multiple copies of the plasmid in the cell. The plasmid may be pVAX1, pCEP4, or pREP4 from Invitrogen (San Diego, CA), which may contain the Epstein Barr virus origin of replication and the nuclear antigen EBNA-1 coding region, which may produce high copy episomal replication without integration. The backbone of the plasmid may be pAV0242. The plasmid may be a replication-deficient adenovirus type 5 (Ad5) plasmid.

[0118] The plasmid can be pSE420 (Invitrogen, San Diego, Calif.), which can be used for protein production in Escherichia coli (E. coli). The plasmid can also be pYES2 (Invitrogen, San Diego, Calif.), which can be used for protein production in Saccharomyces cerevisiae strains of yeast. The plasmid can also be of the MAXBAC™ Complete Baculovirus Expression System (Invitrogen, San Diego, Calif.), which can be used for protein production in insect cells. The plasmid can also be pcDNAI or pcDNA3 (Invitrogen, San Diego, Calif.), which can be used for protein production in mammalian cells such as Chinese Hamster Ovary (CHO) cells.

[0119] RNA In one embodiment, the nucleic acid is an RNA molecule. In one embodiment, the RNA molecule is transcribed from a DNA sequence. Thus, in one embodiment, the invention provides an RNA molecule encoding one or more of the synthetic antibodies of the invention. The RNA can be positive-stranded. Thus, in some embodiments, the RNA molecule can be translated by a cell without the need for any intervening replication step, such as reverse transcription. The RNA molecule useful in the invention can have a 5' cap (e.g., 7-methylguanosine). This cap can improve the in vivo translation of the RNA. The 5' nucleotide of the RNA molecule useful in the invention can have a 5' triphosphate group. In capped RNA, this can be linked to the 7-methylguanosine via a 5'-5' bridge. The RNA molecule can have a 3' poly-A tail. It can also include a poly-A polymerase recognition sequence (e.g., AAUAAA) near its 3' end. The RNA molecule useful in the invention can be single-stranded. The RNA molecule useful in the invention can include synthetic RNA. In some embodiments, the RNA molecule is a naked RNA molecule. In one embodiment, the RNA molecule is included within a vector.

[0120] In one embodiment, the RNA has 5' and 3' UTRs. In one embodiment, the 5' UTR is 0-3000 nucleotides long. The length of the 5' and 3' UTR sequences added to the coding region can be altered by different methods, including but not limited to designing PCR primers that anneal to different regions of the UTR. Using this approach, one skilled in the art can modify the 5' and 3' UTR lengths required to achieve optimal translation efficiency after transfection of the transcribed RNA.

[0121] The 5' and 3' UTRs can be naturally occurring, endogenous 5' and 3' UTRs for the gene of interest. Alternatively, UTR sequences that are not endogenous to the gene of interest can be added by incorporating UTR sequences into forward and reverse primers, or by any other modification of the template. The use of UTR sequences that are not endogenous to the gene of interest can be useful for modifying the stability and / or translation efficiency of RNA. For example, it is known that AU-rich elements in 3' UTR sequences can increase the stability of RNA. Thus, 3' UTRs can be selected or designed to increase the stability of transcribed RNA based on the properties of UTRs that are well known in the art.

[0122] In one embodiment, the 5'UTR may contain the Kozak sequence of the endogenous gene. Alternatively, when a 5'UTR that is not endogenous to the gene of interest is added by PCR as described above, the consensus Kozak sequence can be redesigned by adding the 5'UTR sequence. The Kozak sequence can increase the efficiency of translation of some RNA transcripts, but it does not appear to be required to allow efficient transcription for all RNAs. The Kozak sequence requirement for many RNAs is known in the art. In another embodiment, the 5'UTR may be derived from an RNA virus, whose RNA genome is stable in cells. In another embodiment, various nucleotide analogs can be used in the 3' or 5'UTR to prevent exonuclease degradation of the RNA.

[0123] In one embodiment, the RNA has a cap at both the 5' end and a 3' poly(A) tail, which determines ribosome binding, translation initiation, and stability of the RNA in the cell.

[0124] In one embodiment, the RNA is a nucleoside-modified RNA. Nucleoside-modified RNA has certain advantages over unmodified RNA, including, for example, increased stability, low or no natural immunogenicity, and improved translation.

[0125] Circular and Linear Vectors The one or more vectors may be circular plasmids (e.g., autonomously replicating plasmids with a replication origin) that transform the target cell by integration into the cell genome or may exist extrachromosomally. The vectors may be pVAX, pcDNA3.0, or provax, or any other expression vector capable of expressing the heavy and / or light chain polypeptides encoded by the recombinant nucleic acid sequence construct.

[0126] Also provided herein is a linear nucleic acid, or linear expression cassette ("LEC"), that can be efficiently delivered to a subject via electroporation and express the heavy and / or light chain polypeptides encoded by the recombinant nucleic acid sequence construct. The LEC can be any linear DNA that does not have any phosphate backbone. The LEC may not include any antibiotic resistance gene and / or phosphate backbone. The LEC may not include other nucleic acid sequences that are not related to the desired gene expression.

[0127] The LEC can be derived from any plasmid that can be linearized. The plasmid may be capable of expressing the heavy and / or light chain polypeptides encoded by the recombinant nucleic acid sequence construct. The plasmid can be pNP (Puerto Rico / 34) or pM2 (New Caledonia / 99). The plasmid can be WLV009, pVAX, pcDNA3.0, or provax, or any other expression vector capable of expressing the heavy and / or light chain polypeptides encoded by the recombinant nucleic acid sequence construct.

[0128] The LEC can be pcrM2. The LEC can be pcrNP. The pcrNP and pcrMR can be derived from pNP (Puerto Rico / 34) and pM2 (New Caledonia / 99), respectively.

[0129] Methods for preparing vectors Methods are provided herein for preparing one or more vectors in which recombinant nucleic acid sequence constructs are placed. After the final subcloning step, the vectors can be used to inoculate cell cultures in large-scale fermentation tanks using methods known in the art.

[0130] In other embodiments, after the final subcloning step, the vectors can be used in one or more electroporation (EP) devices, which are described in more detail below.

[0131] The one or more vectors can be formulated or manufactured using a combination of known devices and techniques, but preferably they are manufactured using the plasmid manufacturing techniques described in the granted and co-pending U.S. Provisional Patent Application No. 60 / 939,792, filed May 23, 2007. In some examples, the DNA plasmids described herein can be formulated at a concentration of 10 mg / mL or higher. The manufacturing techniques also include or incorporate various devices and protocols commonly known to those skilled in the art in addition to those described in U.S. Patent Application No. 60 / 939,792, including those described in U.S. Patent No. 7,238,522, which is a granted patent issued July 3, 2007. The above applications and patents, U.S. Patent Application No. 60 / 939,792 and U.S. Patent No. 7,238,522, respectively, are incorporated herein in their entirety.

[0132] antibody In some embodiments, the present invention relates to recombinant nucleic acid sequences encoding an antibody, a fragment thereof, a variant thereof, or a combination thereof. The antibody may bind or react with an antigen as described in more detail below. In some embodiments, the antibody is a DNA-encoded monoclonal antibody (DMAb), a fragment thereof, or a variant thereof. In some embodiments, the fragment is an ScFv fragment. In some embodiments, the antibody is a DNA-encoded bispecific T cell engager (BiTE), a fragment thereof, or a variant thereof.

[0133] In some embodiments, an antibody may comprise a set of heavy and light chain complementarity determining regions ("CDRs"), each of which is inserted between a set of heavy and light chain frameworks ("FRs") that provide support for the CDRs and define the spatial relationship of the CDRs to each other. A set of CDRs may comprise three hypervariable regions of a heavy chain V region or a light chain V region. Proceeding from the N-terminus of the heavy or light chain, these regions are designated as "CDR1", "CDR2", and "CDR3", respectively. Thus, an antigen-binding site may comprise six CDRs, including a set of CDRs from each of the heavy chain V region and the light chain V region.

[0134] The proteolytic enzyme papain preferentially cleaves IgG molecules to yield several fragments, two of which (F(ab) fragments) each contain a covalent heterodimer with an intact antigen-binding site. The enzyme pepsin cleaves IgG molecules to yield F(ab') fragments that contain both antigen-binding sites. 2 Thus, an antibody can be provided as a fragment, including a Fab or F(ab') fragment. 2 The Fab may comprise a heavy chain polypeptide and a light chain polypeptide. The heavy chain polypeptide of the Fab may comprise a VH region and a CH1 region. The light chain of the Fab may comprise a VL region and a CL region.

[0135] The antibody may be an immunoglobulin (Ig). The Ig may be, for example, IgA, IgM, IgD, IgE, and IgG. The immunoglobulin may comprise a heavy chain polypeptide and a light chain polypeptide. The heavy chain polypeptide of the immunoglobulin may comprise a VH region, a CH1 region, a hinge region, a CH2 region, and a CH3 region. The light chain polypeptide of the immunoglobulin may comprise a VL region and a CL region.

[0136] The antibody may be a polyclonal or monoclonal antibody. The antibody may be a chimeric antibody, a single chain antibody, an affinity matured antibody, a human antibody, a humanized antibody, or a fully human antibody. A humanized antibody may be an antibody from a non-human species that binds to a desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule.

[0137] The antibody may be a bispecific antibody, which is described in more detail below. The antibody may be a bifunctional antibody, which is also described in more detail below.

[0138] As described above, the antibody may be generated in the subject upon administration of the composition to the subject. The antibody may have a half-life within the subject. In some embodiments, the antibody may be modified to extend or shorten its half-life within the subject. Such modifications are described in more detail below.

[0139] The antibody may be defucosylated, as described in more detail below.

[0140] ScFv antibody In one embodiment, the DMAb of the present invention is a ScFv DMAb. In one embodiment, the ScFv DMAb is directed to a Fab fragment that does not include those of the CH1 and CL regions. Thus, in one embodiment, the ScFv DMAb is directed to a Fab fragment DMAb that includes a VH and a VL. In one embodiment, the ScFv DMAb includes a linker between the VH and the VL. In one embodiment, the ScFv DMAb is a ScFv-Fc DMAb. In one embodiment, the ScFv-Fc DMAb includes a VH, a VL, and a CH2 and a CH3 region. In one embodiment, the ScFv-Fc DMAb includes a linker between the VH and the VL. In one embodiment, the ScFv DMAb of the present invention has modified expression, stability, half-life, antigen binding, heavy-light chain pairing, tissue penetration, or a combination thereof, compared to the parent DMAb.

[0141] In one embodiment, the ScFv DMAb of the invention has at least 1.1 fold, at least 1.2 fold, fold, at least 1.3 fold, at least 1.4 fold, at least 1.5 fold, at least 1.6 fold, at least 1.7 fold, at least 1.8 fold, at least 1.9 fold, at least 2 fold, at least 2.1 fold, at least 2.2 fold, at least 2.3 fold, at least 2.4 fold, at least 2.5 fold, at least 2.6 fold, at least 2.7 fold, at least at least 2.8 fold, at least at least 2.9 fold, at least 3 fold, at least 3.5 fold, at least 4 fold, at least 4.5 fold, at least 5 fold, at least 5.5 fold, at least 6 fold, at least 6.5 fold, at least 7 fold, at least 7.5 fold, at least 8 fold, at least 8.5 fold, at least 9 fold, at least 9.5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, or more than 50 fold higher expression than the parent DMAb.

[0142] In one embodiment, an ScFv DMAb of the invention has at least 1.1 fold, at least 1.2 fold, at least 1.3 fold, at least 1.4 fold, at least 1.5 fold, at least 1.6 fold, at least 1.7 fold, at least 1.8 fold, at least 1.9 fold, at least 2 fold, at least 2.1 fold, at least 2.2 fold, at least 2.3 fold, at least 2.4 fold, at least 2.5 fold, at least 2.6 fold, at least 2.7 fold, at least at least 2.8 fold, at least at least 2.9 fold, at least 3 fold, at least 3.5 fold, at least 4 fold, at least 4.5 fold, at least 5 fold, at least 5.5 fold, at least 6 fold, at least 6.5 fold, at least 7 fold, at least 7.5 fold, at least 8 fold, at least 8.5 fold, at least 9 fold, at least 9.5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, or more than 50 fold greater antigen binding than the parent DMAb.

[0143] In one embodiment, the ScFv DMAb of the invention has a half-life that is at least 1.1 fold, at least 1.2 fold, at least 1.3 fold, at least 1.4 fold, at least 1.5 fold, at least 1.6 fold, at least 1.7 fold, at least 1.8 fold, at least 1.9 fold, at least 2 fold, at least 2.1 fold, at least 2.2 fold, at least 2.3 fold, at least 2.4 fold, at least 2.5 fold, at least 2.6 fold, at least 2.7 fold, at least at least 2.8 fold, at least at least 2.9 fold, at least 3 fold, at least 3.5 fold, at least 4 fold, at least 4.5 fold, at least 5 fold, at least 5.5 fold, at least 6 fold, at least 6.5 fold, at least 7 fold, at least 7.5 fold, at least 8 fold, at least 8.5 fold, at least 9 fold, at least 9.5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, or more than 50 fold longer than the parent DMAb.

[0144] In one embodiment, the ScFv DMAb of the invention has at least 1.1 fold, at least 1.2 fold, at least 1.3 fold, at least 1.4 fold, at least 1.5 fold, at least 1.6 fold, at least 1.7 fold, at least 1.8 fold, at least 1.9 fold, at least 2 fold, at least 2.1 fold, at least 2.2 fold, at least 2.3 fold, at least 2.4 fold, at least 2.5 fold, at least 2.6 fold, at least 2.7 fold, at least at least 2.8 fold, at least at least 2.9 fold, at least 3 fold, at least 3.5 fold, at least 4 fold, at least 4.5 fold, at least 5 fold, at least 5.5 fold, at least 6 fold, at least 6.5 fold, at least 7 fold, at least 7.5 fold, at least 8 fold, at least 8.5 fold, at least 9 fold, at least 9.5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, or more than 50 fold greater stability than the parent DMAb.

[0145] In one embodiment, the ScFv DMAb of the invention has tissue penetration that is at least 1.1 fold, at least 1.2 fold, at least 1.3 fold, at least 1.4 fold, at least 1.5 fold, at least 1.6 fold, at least 1.7 fold, at least 1.8 fold, at least 1.9 fold, at least 2 fold, at least 2.1 fold, at least 2.2 fold, at least 2.3 fold, at least 2.4 fold, at least 2.5 fold, at least 2.6 fold, at least 2.7 fold, at least at least 2.8 fold, at least at least 2.9 fold, at least 3 fold, at least 3.5 fold, at least 4 fold, at least 4.5 fold, at least 5 fold, at least 5.5 fold, at least 6 fold, at least 6.5 fold, at least 7 fold, at least 7.5 fold, at least 8 fold, at least 8.5 fold, at least 9 fold, at least 9.5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, or more than 50 fold, greater than the parent DMAb.

[0146] In one embodiment, an ScFv DMAb of the invention has at least 1.1 fold, at least 1.2 fold, at least 1.3 fold, at least 1.4 fold, at least 1.5 fold, at least 1.6 fold, at least 1.7 fold, at least 1.8 fold, at least 1.9 fold, at least 2 fold, at least 2.1 fold, at least 2.2 fold, at least 2.3 fold, at least 2.4 fold, at least 2.5 fold, at least 2.6 fold, at least 2.7 fold, at least at least 2.8 fold, at least at least 2.9 fold, at least 3 fold, at least 3.5 fold, at least 4 fold, at least 4.5 fold, at least 5 fold, at least 5.5 fold, at least 6 fold, at least 6.5 fold, at least 7 fold, at least 7.5 fold, at least 8 fold, at least 8.5 fold, at least 9 fold, at least 9.5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, or more than 50 fold greater heavy chain-light chain pairing than the parent DMAb.

[0147] In one embodiment, the anti-HER2scFv antibody comprises an amino acid sequence that is at least 90% homologous to the amino acid sequence of SEQ ID NO: 66, or a fragment of an amino acid sequence that is at least 90% homologous to the amino acid sequence of SEQ ID NO: 66. In one embodiment, the anti-HER2scFv antibody comprises an amino acid sequence of SEQ ID NO: 66, or a fragment of an amino acid sequence of SEQ ID NO: 66. In one embodiment, the anti-HER2scFv antibody comprises an amino acid sequence that is at least 90% homologous to the amino acid sequence encoded by SEQ ID NO: 65, or a fragment of an amino acid sequence that is at least 90% homologous to the amino acid sequence encoded by one of SEQ ID NOs: 65. In one embodiment, the anti-HER2scFv antibody comprises an amino acid sequence encoded by SEQ ID NO: 65, or a fragment of an amino acid sequence encoded by SEQ ID NO: 65.

[0148] Monoclonal antibodies In one embodiment, the present invention provides anti-HER2 antibodies. The antibodies include intact monoclonal antibodies and immunologically active fragments (e.g., Fab or (Fab) 2 The antibody may be a monoclonal antibody fragment, a monoclonal antibody heavy chain, or a monoclonal antibody light chain.

[0149] An antibody may comprise a set of heavy and light chain complementarity determining regions ("CDRs"), each of which is inserted between a set of heavy and light chain frameworks ("FRs") that provide support for the CDRs and define the spatial relationship of the CDRs to each other. A set of CDRs may comprise three hypervariable regions of a heavy chain V region or a light chain V region. Proceeding from the N-terminus of a heavy or light chain, these regions are designated as "CDR1", "CDR2", and "CDR3", respectively. Thus, an antigen-binding site may comprise six CDRs, including a set of CDRs from each of a heavy chain V region and a light chain V region.

[0150] The antibody may be an immunoglobulin (Ig). The Ig may be, for example, IgA, IgM, IgD, IgE, and IgG. The immunoglobulin may comprise a heavy chain polypeptide and a light chain polypeptide. The heavy chain polypeptide of the immunoglobulin may comprise a VH region, a CH1 region, a hinge region, a CH2 region, and a CH3 region. The light chain polypeptide of the immunoglobulin may comprise a VL region and a CL region.

[0151] In one embodiment, the anti-HER2 antibody is optimized for expression in humans. In one embodiment, the anti-HER2 antibody comprises an amino acid sequence that is at least 90% homologous to the amino acid sequence of SEQ ID NO: 62, or a fragment of an amino acid sequence that is at least 90% homologous to the amino acid sequence of SEQ ID NO: 62. In one embodiment, the anti-HER2 antibody comprises an amino acid sequence of SEQ ID NO: 62, or a fragment of an amino acid sequence of SEQ ID NO: 62. In one embodiment, the anti-HER2 antibody comprises an amino acid sequence that is at least 90% homologous to the amino acid sequence encoded by SEQ ID NO: 61, or a fragment of an amino acid sequence that is at least 90% homologous to the amino acid sequence encoded by one of SEQ ID NO: 61. In one embodiment, the anti-HER2 antibody comprises an amino acid sequence encoded by SEQ ID NO: 61, or a fragment of an amino acid sequence encoded by SEQ ID NO: 61.

[0152] In one embodiment, the anti-HER2 antibody is optimized for expression in mice. In one embodiment, the anti-HER2 antibody comprises an amino acid sequence that is at least 90% homologous to the amino acid sequence of SEQ ID NO: 64, or a fragment of an amino acid sequence that is at least 90% homologous to the amino acid sequence of SEQ ID NO: 64. In one embodiment, the anti-HER2 antibody comprises an amino acid sequence of SEQ ID NO: 64, or a fragment of an amino acid sequence of SEQ ID NO: 64. In one embodiment, the anti-HER2 antibody comprises an amino acid sequence that is at least 90% homologous to the amino acid sequence encoded by SEQ ID NO: 61, or a fragment of an amino acid sequence that is at least 90% homologous to the amino acid sequence encoded by one of SEQ ID NOs: 63. In one embodiment, the anti-HER2 antibody comprises an amino acid sequence encoded by SEQ ID NO: 63, or a fragment of an amino acid sequence encoded by SEQ ID NO: 63.

[0153] Bispecific T cell engagers As described above, the recombinant nucleic acid sequence can encode a bispecific T cell engager (BiTE), a fragment thereof, a variant thereof, or a combination thereof. The antigen targeting domain of the BiTE can bind to or react with an antigen, as described in more detail below.

[0154] The antigen targeting domain of a BiTE may comprise an antibody, a fragment thereof, a variant thereof, or a combination thereof. The antigen targeting domain of a BiTE may comprise a set of heavy and light chain complementarity determining regions ("CDRs"), each of which is inserted between a set of heavy and light chain frameworks ("FRs") that provide support for the CDRs and define the spatial relationship of the CDRs relative to each other. The CDR set may comprise three hypervariable regions of the heavy chain V region or the light chain V region. Proceeding from the N-terminus of the heavy or light chain, these regions are designated as "CDR1", "CDR2", and "CDR3", respectively. Thus, the antigen binding domain may comprise six CDRs, including a set of CDRs from each of the heavy chain V region and the light chain V region.

[0155] The proteolytic enzyme papain preferentially cleaves IgG molecules to yield several fragments, two of which (F(ab) fragments) each contain a covalent heterodimer with an intact antigen-binding site. The enzyme pepsin cleaves IgG molecules to yield F(ab') fragments that contain both antigen-binding sites. 2 Thus, the antigen targeting domain of a BiTE may be a Fab or F(ab') fragment. 2 The Fab may comprise a heavy chain polypeptide and a light chain polypeptide. The heavy chain polypeptide of the Fab may comprise a VH region and a CH1 region. The light chain of the Fab may comprise a VL region and a CL region.

[0156] The antigen targeting domain of the BiTE can be an immunoglobulin (Ig). The Ig can be, for example, IgA, IgM, IgD, IgE, and IgG. The immunoglobulin can include a heavy chain polypeptide and a light chain polypeptide. The heavy chain polypeptide of the immunoglobulin can include a VH region, a CH1 region, a hinge region, a CH2 region, and a CH3 region. The light chain polypeptide of the immunoglobulin can include a VL region and a CL region.

[0157] The antigen targeting domain of the BiTE can be a polyclonal or monoclonal antibody. The antibody can be a chimeric antibody, a single chain antibody, an affinity matured antibody, a human antibody, a humanized antibody, or a fully human antibody. A humanized antibody can be an antibody from a non-human species that binds to a desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework region from a human immunoglobulin molecule.

[0158] In one embodiment, at least one of the antigen binding domain and immune cell engaging domain of the DBiTE of the invention is an ScFv DNA-encoded monoclonal antibody (ScFv DMAb), as described in detail above.

[0159] bispecific antibody The recombinant nucleic acid sequence may code for a bispecific antibody, a fragment thereof, a variant thereof, or a combination thereof. A bispecific antibody can bind or react with two antigens, for example, two antigens described in more detail below. A bispecific antibody may be composed of two fragments of the antibodies described herein, thereby allowing the bispecific antibody to bind or react with two desired target molecules, which may include antigens, ligands for receptors, receptors, ligand-binding sites on receptors, ligand-receptor complexes, and markers, which are described in more detail below.

[0160] The present invention provides novel bispecific antibodies comprising a first antigen-binding site that specifically binds to a first target and a second antigen-binding site that specifically binds to a second target, and have particularly advantageous properties such as producibility, stability, binding affinity, biological activity, specific targeting of certain T cells, targeting efficiency, and reduced toxicity. In some examples, there are bispecific antibodies, where the bispecific antibodies bind to the first target with high affinity and the second target with low affinity. In other examples, there are bispecific antibodies, where the bispecific antibodies bind to the first target with low affinity and the second target with high affinity. In other examples, there are bispecific antibodies, where the bispecific antibodies bind to the first target with a desired affinity and the second target with a desired affinity.

[0161] In one embodiment, a bispecific antibody is a bivalent antibody comprising a) a first light chain and a first heavy chain of an antibody that specifically binds to a first antigen, and b) a second light chain and a second heavy chain of an antibody that specifically binds to a second antigen.

[0162] The bispecific antibody molecule according to the present invention may have two binding sites of any desired specificity. In some embodiments, one of the binding sites may be a tumor antigen. In some embodiments, the binding site contained in the Fab fragment is a binding site specific for a tumor antigen. In some embodiments, the binding site contained in the single chain Fv fragment is a binding site specific for a tumor antigen such as CD19, BCMA, CD33, FAP, FSHR, EGFR, PSMA, CD123 or Her2.

[0163] In some embodiments, one of the binding sites of the antibody molecule according to the invention is capable of binding to a T cell specific receptor molecule and / or a natural killer cell (NK cell) specific receptor molecule. The T cell specific receptor is the so-called "T cell receptor" (TCR) that allows the T cell to bind to an epitope / antigen presented by another cell, called an antigen presenting cell or APC, and thereby be activated and respond to it, if additional signals are present. T cell receptors are known to resemble the Fab fragments of naturally occurring immunoglobulins. Generally, they are monovalent, comprising an alpha chain and a beta chain, and in some embodiments, a gamma chain and a delta chain (see above). Thus, in some embodiments, the TCR is a TCR (alpha / beta) and in some embodiments, a TCR (gamma / delta). The T cell receptor forms a complex with the CD3 T cell co-receptor. CD3 is a protein complex and consists of four different chains. In mammals, the complex comprises the CD3 gamma chain, the CD36 chain, and two CD3E chains. These chains associate with molecules known as the T cell receptor (TCR) and ζ chain to generate an activation signal within the T lymphocyte. Thus, in some embodiments, the T cell specific receptor is the CD3 T cell co-receptor. In some embodiments, the T cell specific receptor is the protein CD28, which is also expressed on T cells. CD28 can provide the costimulatory signal required for T cell activation. CD28 plays an important role in T cell proliferation and survival, cytokine production, and type 2 T helper development. A further example of a T cell specific receptor is CD134, also referred to as Ox40. CD134 / OX40 is expressed 24-72 hours after activation and can be taken to define a secondary costimulatory molecule. Another example of a T cell receptor is 4-1 BB, which can bind to the 4-1 BB-ligand on antigen presenting cells (APC), thereby generating a costimulatory signal for the T cell. Another example of a receptor found primarily on T cells is CD5, which is also found at lower levels on B cells.A further example of a receptor that modulates T cell function is CD95, also known as the Fas receptor, which mediates apoptotic signaling by Fas-ligand expressed on the surface of other cells. CD95 has been reported to regulate TCR / CD3-driven signaling pathways in resting T lymphocytes.

[0164] An example of a NK cell-specific receptor molecule is CD16, low affinity Fc receptor, and NKG2D. An example of a receptor molecule present on the surface of both T cells and natural killer (NK) cells is CD2 and other members of the CD2-superfamily. CD2 can act as a costimulatory molecule on T cells and NK cells.

[0165] In some embodiments, a first binding site of the antibody molecule binds to a tumor antigen and a second binding site binds to a T cell-specific receptor molecule and / or a natural killer (NK) cell-specific receptor molecule.

[0166] In some embodiments, a first binding site of the antibody molecule binds to CD19, BCMA, CD33, FAP, FSHR, EGFR, PSMA, CD123 or Her2, and a second binding site binds to a T cell specific receptor molecule and / or a natural killer (NK) cell specific receptor molecule. In some embodiments, a first binding site of the antibody molecule binds to CD19, BCMA, CD33, FAP, FSHR, EGFR, PSMA, CD123 or Her2, and a second binding site binds to one of CD3, TCR, CD28, CD16, NKG2D, Ox40, 4-1BB, CD2, CD5, CD40, FcgR, FceR, FcaR, and CD95. In some embodiments, a first binding site of the antibody molecule binds to CD19, BCMA, CD33, FAP, FSHR, EGFR, PSMA, CD123, or Her2, and a second binding site binds to CD3.

[0167] In some embodiments, the first binding site of the antibody molecule binds to a T cell specific receptor molecule and / or a natural killer (NK) cell specific receptor molecule, and the second binding site binds to a tumor antigen. In some embodiments, the first binding site of the antibody binds to a T cell specific receptor molecule and / or a natural killer (NK) cell specific receptor molecule, and the second binding site binds to CD19, BCMA, CD33, FAP, FSHR, EGFR, PSMA, CD123, or Her2. In some embodiments, the first binding site of the antibody binds to one of CD3, TCR, CD28, CD16, NKG2D, Ox40, 4-1BB, CD2, CD5, CD40, FcgR, FceR, FcaR, and CD95, and the second binding site binds to CD19, BCMA, CD33, FAP, FSHR, EGFR, PSMA, CD123, or Her2. In some embodiments, a first binding site of the antibody binds to CD3 and a second binding site binds to CD19, BCMA, CD33, FAP, FSHR, EGFR, PSMA, CD123, or Her2.

[0168] In one embodiment, a bispecific antibody of the invention comprises a DBiTE that comprises one or more scFv antibody fragments described herein, thereby enabling the DBiTE to bind or react with a desired target molecule.

[0169] In one embodiment, the DBiTE comprises a nucleic acid molecule encoding a first scFv specific for binding to a target disease-specific antigen linked to a second scFv specific for binding to a T cell-specific receptor molecule. The linkage may arrange the first and second domains in any order, for example, in one embodiment, the nucleotide sequence encoding the scFv specific for binding to the target disease-specific antigen is oriented 5' (or upstream) to the nucleotide sequence encoding the scFv specific for binding to the T cell-specific receptor molecule. In another embodiment, the nucleotide sequence encoding the scFv specific for binding to the target disease-specific antigen is oriented 3' (or downstream) to the nucleotide sequence encoding the scFv specific for binding to the T cell-specific receptor molecule.

[0170] Bifunctional antibody The recombinant nucleic acid sequence may code for a bifunctional antibody, a fragment thereof, a variant thereof, or a combination thereof. The bifunctional antibody may bind or react with the antigen described below. The bifunctional antibody may also be modified to provide the antibody with additional functionality beyond antigen recognition and binding. Such modifications may include, but are not limited to, binding to factor H or a fragment thereof. Factor H is a soluble regulator of complement activation and may therefore contribute to immune responses via complement-mediated lysis (CML).

[0171] Antibody half-life extension As described above, synthetic antibodies (e.g., DMAb, ScFv antibody fragments, DICE, or DBiTE) can be modified to extend or shorten the half-life of the antibody in a subject. The modification can extend or shorten the half-life of the antibody in the serum of the subject.

[0172] The modification can be present in the constant region of the antibody.The modification can be one or more amino acid substitutions in the constant region of the antibody that extend the half-life of the antibody compared to the half-life of the antibody that does not contain one or more amino acid substitutions.The modification can be one or more amino acid substitutions in the CH2 domain of the antibody that extend the half-life of the antibody compared to the half-life of the antibody that does not contain one or more amino acid substitutions.

[0173] In some embodiments, the one or more amino acid substitutions in the constant region may include replacing a methionine residue in the constant region with a tyrosine residue, a serine residue in the constant region with a threonine residue, a threonine residue in the constant region with a glutamine residue, or any combination thereof, thereby increasing the half-life of the antibody.

[0174] In other embodiments, the one or more amino acid substitutions in the constant region may include replacing a methionine residue in the CH2 domain with a tyrosine residue, a serine residue in the CH2 domain with a threonine residue, a threonine residue in the CH2 domain with a glutamine residue, or any combination thereof, thereby increasing the half-life of the antibody.

[0175] Defucosylation The recombinant nucleic acid sequence may code for a non-fucosylated antibody (i.e., a defucosylated or non-fucosylated antibody), a fragment thereof, a variant thereof, or a combination thereof. Fucosylation involves the addition of the sugar fucose to a molecule, for example, the attachment of fucose to N-glycans, O-glycans, and glycolipids. Thus, in a defucosylated antibody, fucose is not attached to the carbohydrate chain of the constant region. This lack of fucosylation may then improve FcγRIIIa binding and antibody-directed cellular cytotoxicity (ADCC) activity by the antibody compared to a fucosylated antibody. Thus, in some embodiments, a nonfucosylated antibody may exhibit increased ADCC activity compared to a fucosylated antibody.

[0176] The antibody may be modified to prevent or inhibit the fucosylation of the antibody. In some embodiments, such modified antibodies may exhibit increased ADCC activity compared to unmodified antibodies. The modification may be in the heavy chain, the light chain, or a combination thereof. The modification may be one or more amino acid substitutions in the heavy chain, one or more amino acid substitutions in the light chain, or a combination thereof.

[0177] antigen In one embodiment, the synthetic antibody (e.g., DMAb, ScFv antibody fragment, DICE or DBiTE) is directed to an antigen or a fragment or variant thereof. The antigen can be a nucleic acid sequence, an amino acid sequence, a polysaccharide, or a combination thereof. The nucleic acid sequence can be DNA, RNA, cDNA, a variant thereof, a fragment thereof, or a combination thereof. The amino acid sequence can be a protein, a peptide, a variant thereof, a fragment thereof, or a combination thereof. The polysaccharide can be a nucleic acid encoded polysaccharide.

[0178] The antigen can be a tumor antigen. The antigen can be associated with an increased risk of cancer development or progression. In one embodiment, the antigen can be CD19, BCMA, CD33, FAP, FSHR, EGFR, PSMA, CD123, or Her2.

[0179] In one embodiment, the synthetic DNA encoded bispecific immune cell engager of the invention targets two or more antigens. In one embodiment, at least one antigen of the bispecific antibody is a tumor antigen. In one embodiment, at least one antigen of the bispecific antibody is a T cell activation antigen.

[0180] Tumor antigens The antigen-binding domain of a synthetic antibody of the invention (e.g., a DMAb, an ScFv antibody fragment, a DICE, or a DBiTE) can interact with a tumor antigen. In the context of the present invention, a "tumor antigen" or a "hyperproliferative disorder antigen" or an "antigen associated with a hyperproliferative disorder" refers to an antigen that is common to a particular hyperproliferative disorder, such as cancer.

[0181] The type of tumor antigen referred to in the present invention can be tumor-specific antigen (TSA) or tumor-associated antigen (TAA). TSA is unique to tumor cells and does not occur in other cells in the body. TAA antigens are not unique to tumor cells, but instead are also expressed on normal cells under conditions that cannot induce a state of immunological tolerance to the antigen. Expression of antigens on tumors can occur under conditions that allow the immune system to respond to the antigen. TAA can be an antigen that is expressed on normal cells during fetal development, when the immune system is immature and unable to respond, or an antigen that is usually present at very low levels on normal cells, but is expressed at much higher levels on tumor cells.

[0182] The antigens discussed herein are included by way of example only: the list is not intended to be exhaustive, and further examples will be readily apparent to those of skill in the art.

[0183] Tumor antigens are proteins produced by tumor cells that elicit an immune response, particularly a T cell-mediated immune response. The choice of antigen-binding moiety of the invention depends on the particular type of cancer being treated. Tumor antigens are well known in the art and include, for example, glioma-associated antigen, carcinoembryonic antigen (CEA), β-human chorionic gonadotropin, alpha fetoprotein (AFP), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CAIX, human telomerase reverse transcriptase, RU1, RU2 (AS), intestinal carboxylesterase, mut hsp70-2, M-CSF, prostase, prostate specific antigen (PSA), PAP, NY-ESO-1, LAGE-1a, p53, prostein, PSMA, Her2, survivin and telomerase, prostate cancer tumor antigen-1 (PCTA-1), MAGE, ELF2M, neutrophil elastase, ephrin B2, CD22, insulin growth factor (IGF)-I, IGF-II, IGF-I receptor, and mesothelin.

[0184] Illustrative examples of tumor-associated surface antigens are CD10, CD19, CD20, CD22, CD33, CD123, B-cell maturation antigen (BCMA), Fms-like tyrosine kinase 3 (FLT-3, CD135), chondroitin sulfate proteoglycan 4 (CSPG4, melanoma-associated chondroitin sulfate proteoglycan), epidermal growth factor receptor (EGFR), Her2, Her3, IGFR, CD133, IL3R, fibroblast activation protein (FAP), CDCP1, Derlin1, tenascin, frizzled1-10, vascular antigen VEGFR2 (KDR / FLK1), VEGFR3 (FLT4, CD309), PDGFR-alpha (CD140a), PDGFR-beta (CD140b), endoglin, CLEC14, Tem1-8, and Tie2. Further examples may include A33, CAMPATH-1 (CDw52), carcinoembryonic antigen (CEA), carboanhydrase IX (MN / CAIX), CD21, CD25, CD30, CD34, CD37, CD44v6, CD45, CD133, de2-7EGFR, EGFRvIII, EpCAM, Ep-CAM, folate binding protein, G250, Fms-like tyrosine kinase 3 (FLT-3, CD135), follicle-stimulating hormone receptor (FSHR), c-Kit (CD117), CSF1R (CD115), HLA-DR, IGFR, IL-2 receptor, IL3R, MCSP (melanoma-associated cell surface chondroitin sulfate proteoglycan), Muc-1, prostate-specific membrane antigen (PSMA), prostate stem cell antigen (PSCA), prostate-specific antigen (PSA), and TAG-72. Examples of antigens expressed in the extracellular matrix of tumors are tenascin and fibroblast activation protein (FAP).

[0185] In one embodiment, the tumor antigen is a hormone or a fragment thereof that can be used to target a specific receptor. Examples include, but are not limited to, FSH hormone, LH hormone, TSH hormone, or fragments thereof.

[0186] Non-limiting examples of TSA or TAA antigens include: MART-1 / MelanA (MART-I), gp100 (Pmel17), tyrosinase, TRP-1, TRP-2, and tumor-specific multilineage antigens such as MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, p15, and the like; overexpressed embryonic antigens such as CEA; overexpressed oncogenes and mutated tumor suppressor genes such as p53, Ras, HER-2 / neu, and the like; unique tumor antigens resulting from chromosomal translocations; for example, BCR-ABL, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR; and viral antigens, such as differentiation antigens such as Epstein-Barr virus antigen EBVA and human papilloma virus (HPV) antigens E6 and E7. Other large protein-based antigens include TSP-180, MAGE-4, MAGE-5, MAGE-6, RAGE, NY-ESO, p185erbB2, p180erbB-3, c-met, nm-23H1, PSA, TAG-72, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, beta-catenin, CDK4, Mum-1, p 15, p 16, 43-9F, 5T4, 791Tgp72, alpha-fetoprotein, beta-HCG, BCA225, BTAA, CA 125, CA 15-3\CA27.29\BCAA, CA 195, CA 242, CA-50, CAM43, CD68\P1, CO-029, FGF-5, G250, Ga733\EpCAM, HTgp-175, M344, MA-50, MG7-Ag, MOV18, NB / 70K, NY-CO-1, RCAS1, SDCCAG16, TA-90\Mac-2 binding protein\cyclophin C-related protein, TAAL6, TAG72, TLP, and TPS.

[0187] Aspects of the invention include compositions comprising a synthetic antibody (e.g., a DMAb, an ScFv antibody fragment, a DICE, or a DBiTE), or a biologically functional fragment or variant thereof, capable of generating an immune response in a subject, for enhancing an immune response to an antigen in a subject in need thereof. In some embodiments, the antigen is CD19, BCMA, CD33, FAP, FSHR, EGFR, PSMA, CD123, or Her2. In some embodiments, the synthetic antibody of the invention is a DBiTE comprising an scFv targeting CD19, BCMA, CD33, FAP, FSHR, EGFR, PSMA, CD123, or Her2.

[0188] T cell specific receptor In one embodiment, a DBiTE or DICE of the invention comprises an scFv of a T cell specific receptor, including but not limited to CD3, TCR, CD28, CD16, NKG2D, Ox40, 4-1BB, CD2, CD5, CD40, FcgR, FceR, FcaR, and CD95.

[0189] Excipients and other components of the composition The composition may further comprise a pharmaceutically acceptable excipient.The pharmaceutically acceptable excipient may be a functional molecule such as vehicle, carrier or diluent.The pharmaceutically acceptable excipient may be a transfection promoter, which may comprise surfactants such as immune stimulating complexes (ISCOMS), Freund's incomplete adjuvant, LPS analogs including monophosphoryl lipid A, muramyl peptides, quinone analogs, vesicles such as squalene and squalene, hyaluronic acid, lipids, liposomes, calcium ions, viral proteins, polyanions, polycations, or nanoparticles, or other known transfection promoters.

[0190] The transfection facilitating agent is a polyanion, a polycation, including poly-L-glutamic acid (LGS), or a lipid. The transfection facilitating agent is poly-L-glutamic acid, and the poly-L-glutamic acid may be present in the composition at a concentration of less than 6 mg / ml. The transfection facilitating agent may also include surfactants, such as immune stimulating complexes (ISCOMS), Freund's incomplete adjuvant, LPS analogs, including monophosphoryl lipid A, muramyl peptides, quinone analogs, and vesicles, such as squalene and squalene, and hyaluronic acid may also be used administered with the composition. The composition may also include transfection facilitating agents, such as lipids, liposomes, including lecithin liposomes or other liposomes known in the art, such as DNA-liposome mixtures (see, for example, WO9324640), calcium ions, viral proteins, polyanions, polycations, or nanoparticles, or other known transfection facilitating agents. The transfection facilitating agent is a polyanion, a polycation, including poly-L-glutamic acid (LGS), or a lipid. The concentration of the transfection agent in the composition is less than 4 mg / ml, less than 2 mg / ml, less than 1 mg / ml, less than 0.750 mg / ml, less than 0.500 mg / ml, less than 0.250 mg / ml, less than 0.100 mg / ml, less than 0.050 mg / ml, or less than 0.010 mg / ml.

[0191] The composition may further comprise a gene enhancer as described in US patent application Ser. No. 021,579, filed Apr. 1, 1994, which is incorporated by reference in its entirety.

[0192] The composition may contain DNA in an amount of about 1 nanogram to about 100 milligrams, about 1 microgram to about 10 milligrams, or preferably about 0.1 microgram to about 10 milligrams, or more preferably about 1 milligram to about 2 milligrams. In some preferred embodiments, the composition according to the present invention contains about 5 nanograms to about 1000 micrograms of DNA. In some preferred embodiments, the composition may contain about 10 nanograms to about 800 micrograms of DNA. In some preferred embodiments, the composition may contain about 0.1 to about 500 micrograms of DNA. In some preferred embodiments, the composition may contain about 1 to about 350 micrograms of DNA. In some preferred embodiments, the composition may contain about 25 to about 250 micrograms, about 100 to about 200 micrograms, about 1 nanogram to 100 milligrams, about 1 microgram to about 10 milligrams, about 0.1 micrograms to about 10 milligrams, about 1 milligram to about 2 milligrams, about 5 nanograms to about 1000 micrograms, about 10 nanograms to about 800 micrograms, about 0.1 to about 500 micrograms, about 1 to about 350 micrograms, about 25 to about 250 micrograms, or about 100 to about 200 micrograms of DNA.

[0193] The composition may be formulated according to the mode of administration used. The injectable pharmaceutical composition may be sterile, pyrogen-free, and particulate-free. An isotonic formulation or solution may be used. Additives for isotonicity may include sodium chloride, dextrose, mannitol, sorbitol, and lactose. The composition may include a vasoconstrictor. The isotonic solution may include phosphate buffered saline. The composition may further include a stabilizer including gelatin and albumin. The stabilizer may allow the formulation including LGS or polycation or polyanion to be stable for an extended period of time at room or ambient temperature.

[0194] Methods for producing synthetic antibodies The present invention also relates to a method for producing synthetic antibodies. The method may include administering the composition to a subject in need thereof by using a delivery method described in more detail below. Thus, the synthetic antibodies are produced in the subject or in vivo upon administration of the composition to the subject.

[0195] The method may also include introducing the composition into one or more cells, so that the synthetic antibody may be generated or produced within the one or more cells. The method may further include introducing the composition into one or more tissues, such as, but not limited to, skin and muscle, so that the synthetic antibody may be generated or produced in the one or more tissues.

[0196] Methods for delivering the composition The present invention also relates to a method for delivering the composition to a subject in need thereof.The delivery method can include administering the composition to a subject.Administering can include, but is not limited to, DNA injection with or without in vivo electroporation, liposome-mediated delivery, and nanoparticle-facilitated delivery.

[0197] The mammal to which the composition is delivered can be a human, a primate, a non-human primate, a cow, a cattle, a sheep, a goat, an antelope, a bison, a water buffalo, a bison, a bovid, a deer, a hedgehog, an elephant, a llama, an alpaca, a mouse, a rat, and a chicken.

[0198] The composition may be administered by different routes, including orally, parenterally, sublingually, transdermally, rectally, transmucosally, topically, via inhalation, via buccal administration, intrathoracically, intravenously, intraarterially, intraperitoneally, subcutaneously, intramuscularly, intranasally, intrathecally and intraarticularly, or combinations thereof. For veterinary use, the composition may be administered in a suitably tolerated formulation in accordance with normal veterinary practice. A veterinarian can readily determine the most appropriate dosing regimen and route of administration for a particular animal. The composition may be administered by conventional syringes, needleless injection devices, "microprojectile bombardment gone guns," or other physical methods such as electroporation ("EP"), "hydrodynamic methods," or ultrasound.

[0199] Electroporation Administration of the composition via electroporation can be accomplished using an electroporation device that can be configured to deliver an energy pulse to the desired tissue of a mammal that is effective to form reversible pores in the cell membrane, and preferably the energy pulse is a constant current similar to the preset current input by the user. The electroporation device can include an electroporation component and an electrode assembly or a handle assembly. The electroporation component can include or incorporate one or more of the various elements of an electroporation device, including a controller, a current waveform generator, an impedance tester, a waveform logger, an input element, a status reporting element, a communication port, a memory component, a power supply, and a power switch. Electroporation can be accomplished using an in vivo electroporation device, such as the CELLECTRA EP system (Inovio Pharmaceuticals, Plymouth Meeting, PA) or the Elgen electroporator (Inovio Pharmaceuticals, Plymouth Meeting, PA), to facilitate the transfection of cells with plasmids.

[0200] The electroporation component may function as one element of the electroporation device, and the other elements are separate elements (or components) that communicate with the electroporation component. The electroporation component may function as more than one element of the electroporation device, and may communicate with yet other elements of the electroporation device that are separate from the electroporation component. The elements of the electroporation device that are present as part of one electromechanical or mechanical device may not be limited, as the elements can function as one device or as separate elements that communicate with each other. The electroporation component may be capable of delivering an energy pulse that generates a constant current in the desired tissue, and includes a feedback mechanism. The electrode assembly may include an electrode array having a plurality of spatially arranged electrodes, and the electrode assembly receives the energy pulse from the electroporation component and delivers it to the desired tissue through the electrodes. At least one of the plurality of electrodes is neutral during delivery of the pulse of energy, measures the impedance of the desired tissue, and communicates the impedance to the electroporation component. The feedback mechanism may receive the measured impedance and adjust the energy pulse delivered by the electroporation component to maintain the constant current.

[0201] The electrodes may deliver pulses of energy in a distributed pattern. The electrodes may deliver pulses of energy in a distributed pattern through control of the electrodes under a programmed sequence, the programmed sequence being input by a user into the electroporation component. The programmed sequence may include a plurality of pulses delivered in a sequence, each pulse of the plurality of pulses being delivered by at least two active electrodes having one indifferent electrode that measures impedance, and subsequent pulses of the plurality of pulses being delivered by a different one of the at least two active electrodes having one indifferent electrode that measures impedance.

[0202] The feedback mechanism may be implemented by either hardware or software. The feedback mechanism may be implemented by an analog closed loop circuit. The feedback occurs every 50 μs, 20 μs, 10 μs, or 1 μs, but is preferably real-time feedback or immediate (i.e., substantially immediate as determined by available techniques for determining response time). The indifferent electrode may measure the impedance in the desired tissue and transmit the impedance to the feedback mechanism, which responds to the impedance and adjusts the energy pulse to maintain the constant current at a value similar to the preset current. The feedback mechanism may maintain the constant current continuously and immediately during the delivery of the pulse of energy.

[0203] Examples of electroporation devices and electroporation methods that can facilitate the delivery of the compositions of the present invention include those described in U.S. Patent No. 7,245,963 by Draghia-Akli et al., U.S. Patent Publication No. 2005 / 0052630 filed by Smith et al., the contents of which are incorporated herein by reference in their entirety.Other electroporation devices and electroporation methods that can be used to facilitate the delivery of the compositions include those provided in U.S. Provisional Patent Application No. 60 / 852,149, filed October 17, 2006, and co-pending, co-owned U.S. Patent Application No. 11 / 874,072, filed October 17, 2007, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 60 / 978,982, filed October 10, 2007, all of which are incorporated herein in their entirety.

[0204] U.S. Patent No. 7,245,963 by Draghia-Akli et al. describes modular electrode systems and their use to facilitate the introduction of biomolecules into cells of selected tissues of an organism or plant. The modular electrode system may include multiple needle electrodes, a hypodermic needle, an electrical connector providing a conductive link from a programmable constant current pulse controller to the multiple needle electrodes, and a power source. An operator can grasp the multiple needle electrodes attached to a support structure and firmly insert them into selected tissues of an organism or plant. The biomolecules are then delivered to the selected tissue via the hypodermic needle. A programmable constant current pulse controller is activated and constant current electrical pulses are applied to the multiple needle electrodes. The applied constant current electrical pulses facilitate the introduction of biomolecules into cells between the multiple electrodes. The entire contents of U.S. Patent No. 7,245,963 are incorporated herein by reference.

[0205] U.S. Patent Publication No. 2005 / 0052630, filed by Smith et al., describes an electroporation device that can be used to effectively facilitate the introduction of biomolecules into cells of selected tissues within a body or plant. The electroporation device includes an electrokinetic device ("EKD device") whose operation is specified by software or firmware. The EKD device generates a series of programmable constant current pulse patterns between electrodes in an array based on user control and input of pulse parameters, and allows for storage and retrieval of current waveform data. The electroporation device also includes a replaceable electrode disk having an array of needle electrodes, a central injection channel for an injection needle, and a removable guide disk. The entire contents of U.S. Patent Publication No. 2005 / 0052630 are incorporated herein by reference.

[0206] The electrode arrays and methods described in US Patent No. 7,245,963 and US Patent Publication No. 2005 / 0052630 can be adapted for deep penetration into tissues such as muscles, as well as other tissues or organs. Due to the configuration of the electrode array, the injection needle (to deliver the selected biomolecule) is also fully inserted into the target organ, and the injection is administered perpendicular to the target tissue in the area pre-delineated by the electrode. The electrodes described in US Patent No. 7,245,963 and US Patent Publication No. 2005 / 005263 are preferably 20 mm long and 21 gauge.

[0207] Additionally, in some embodiments incorporating electroporation devices and their use, it is contemplated that there are electroporation devices as described in the following patents: U.S. Patent No. 5,273,525 issued December 28, 1993, U.S. Patent No. 6,110,161 issued August 29, 2000, U.S. Patent No. 6,261,281 issued July 17, 2001, and U.S. Patent No. 6,958,060 issued October 25, 2005, and U.S. Patent No. 6,939,862 issued September 6, 2005. Additionally, patents encompassing subject matter provided in U.S. Patent No. 6,697,669 issued February 24, 2004, which relates to delivery of DNA using any of a variety of devices, and U.S. Patent No. 7,328,064 issued February 5, 2008, which focuses on methods of injecting DNA, are contemplated herein. The above patents are incorporated by reference in their entirety.

[0208] Treatment method Also provided herein is a method for treating, protecting against, and / or preventing a disease in a subject in need thereof by generating a synthetic antibody (e.g., a DMAb, a scFv fragment, or a DBiTE) in the subject. The method may include administering a composition to the subject. The administration of the composition to the subject may be performed using the delivery methods described above.

[0209] In certain embodiments, the present invention provides a method of treating, protecting against, and / or preventing cancer. In one embodiment, the method treats, protects against, and / or prevents tumor growth. In one embodiment, the method treats, protects against, and / or prevents cancer progression. In one embodiment, the method treats, protects against, and / or prevents cancer metastasis.

[0210] In one embodiment, the present invention provides a method for preventing the growth of benign tumors, such as, but not limited to, uterine fibroids, comprising administering an effective amount of one or more of the compositions of the present invention to a subject diagnosed with a benign tumor.

[0211] Once generated in a subject, the synthetic antibody (e.g., DMAb, scFv fragment, or DBiTE) can bind or react with an antigen. Such binding can neutralize the antigen, block recognition of the antigen by another molecule, e.g., a protein or nucleic acid, and induce or induce an immune response against the antigen, thereby treating, protecting against, and / or preventing a disease associated with the antigen in the subject.

[0212] The composition dose may be 1 μg to 10 mg of active ingredient / kg body weight / dose, and may be 20 μg to 10 mg of ingredient / kg body weight / dose. The composition may be administered every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 days. The number of composition doses for effective treatment may be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0213] cancer treatment The present invention provides methods for treating or preventing cancer, or treating and preventing tumor growth or metastasis. Related aspects of the invention provide methods for preventing, assisting in the prevention, and / or reducing hyperplasia or metastasis of tumor cells in an individual.

[0214] One aspect of the present invention provides a method of inhibiting metastasis in an individual in need thereof, comprising administering to the individual an effective amount of a composition of the present invention. The present invention further provides a method of inhibiting metastasis in an individual in need thereof, comprising administering to the individual an effective amount of any one of the compositions described herein.

[0215] In some embodiments of treating or preventing cancer or treating and preventing metastasis of tumor in an individual in need thereof, a second agent such as an antitumor agent is administered to the individual.In some embodiments, the second agent comprises a second metastasis inhibitor such as a plasminogen antagonist or an adenosine deaminase antagonist.In other embodiments, the second agent is an angiogenesis inhibitor.

[0216] The compositions of the present invention can be used to prevent, abate, minimize, control, and / or lessen cancer in humans and animals. The compositions of the present invention can also be used to slow the rate of primary tumor growth. The compositions of the present invention can be used to stop the spread of cancer cells when administered to a subject in need of treatment. Thus, the compositions of the present invention can be administered as part of a combination therapy with one or more drugs or other agents. When used as part of a combination therapy, the reduction in metastasis and the reduction in primary tumor growth obtained by the compositions of the present invention allows for more effective and efficient use of any pharmaceutical or drug therapy used to treat the patient. In addition, the control of metastasis by the compositions of the present invention gives the subject a greater ability to focus the disease in one location.

[0217] In one embodiment, the present invention provides a method for preventing metastasis of malignant tumors or other cancer cells, as well as a method for reducing tumor growth rate. The method comprises administering an effective amount of one or more of the compositions of the present invention to a subject diagnosed with or having a malignant tumor or cancerous cells.

[0218] The following are non-limiting examples of cancers that may be treated by the methods and compositions of the present invention: acute lymphoblastic; acute myeloid leukemia; adrenal cortical carcinoma; adrenal cortical carcinoma, childhood; appendix cancer; basal cell carcinoma; cholangiocarcinoma, extrahepatic; bladder cancer; bone cancer; osteosarcoma and malignant fibrous histiocytoma; brain stem glioma, childhood; brain tumor, adult; brain tumor, brain stem glioma, childhood; brain tumor, central nervous system atypical teratoid / rhabdoid tumor, childhood; central nervous system embryonal tumor; cerebellar astrocytoma; brain astrocytoma / malignant glioma; craniopharyngioma; ependymomas; ependymoma; medulloblastoma; medulloepithelioma; pineal parenchymal tumor of intermediate differentiation; Supratentorial primitive neuroectodermal tumor and pineoblastoma;visual pathway and hypothalamic glioma;brain and spinal cord tumors;breast cancer;bronchial tumors;Burkitt's lymphoma;carcinoid tumor;carcinoid tumor, gastrointestinal;central nervous system atypical teratoid / rhabdoid tumor;central nervous system germinoma;central nervous system lymphoma;cerebellar astrocytoma;brain astrocytoma / malignant glioma, childhood;cervical cancer;chordoma, childhood;chronic lymphocytic leukemia;chronic myelogenous leukemia;chronic myeloproliferative disorder;colon cancer;colorectal cancer;craniopharyngioma;cutaneous T-cell lymphoma;esophageal cancer;Ewing family of tumors;extragonadal germinoma tumors;extrahepatic bile duct cancer;eye cancer, intraocular melanoma;eye cancer, retinoblastoma;gallbladder cancer;gastric (stomach) cancer;gastrointestinal carcinoid tumors;gastrointestinal stromal tumors (GIST);germ cell tumors, extracranial;germ cell tumors, extragonadal;germ cell tumors, ovarian;gestational trophoblastic tumors;gliomas;pediatric brain stem gliomas;pediatric brain astrocytoma gliomas;pediatric visual pathway and hypothalamic gliomas;hairy cell leukemia;head and neck cancer;hepatocellular (liver) carcinoma;histiocytosis, Langerhans cell;Hodgkin's lymphoma;hypopharyngeal carcinoma;hypothalamic and visual pathway gliomas;intraocular melanoma;islet cell tumors; Kidney (renal cell) carcinoma;Langerhans cell histiocytosis;Laryngeal carcinoma;Leukemia, acute lymphoblastic;Leukemia, acute myeloid;Leukemia, chronic lymphocytic;Leukemia, chronic myeloid;Leukemia, hairy cell;Lip and oral cavity cancer;Liver cancer;Lung cancer, non-small cell;Lung cancer, small cell;Lymphoma, AIDS-related;Lymphoma, Burkitt;Lymphoma, cutaneous T-cell;Lymphoma, Hodgkin;Lymphoma, non-Hodgkin;Lymphoma, primary central nervous system;Macroglobulinemia, Waldenstrom;Malignant fibrous histiocytoma of bone and osteosarcoma;Medulloblastoma;Melanoma;Melanoma, intraocular (eye);Merkel cell carcinoma;Mesothelioma;Metastatic cervical squamous cell carcinoma with occult primary;Oral cancer;Multiple endocrine neoplasia syndrome, (childhood);Multiple myeloma / plasma cell neoplasm;Mycosis;Mycosis;Myelodysplastic syndrome;Myelodysplastic / myeloproliferative disorders;Myeloid leukemia, chronic;Myeloid leukemia, adult acute;Myeloid leukemia, childhood acute;Myeloma, multiple;Myeloproliferative disorders, chronic;Nasal and paranasal sinus cancer;Nasopharyngeal carcinoma;Neuroblastoma;Non-small cell lung cancer;Oral cancer;Oral cavity cancer Cancer);Oropharyngeal cancer;Osteosarcoma and malignant fibrous histiocytoma of bone;Ovarian cancer;Ovarian epithelial carcinoma;Ovarian germ cell tumor;Ovarian low malignant potential tumor;Pancreatic cancer;Pancreatic cancer, islet cell tumor;Papillomatosis;Parathyroid carcinoma;Penile cancer;Pharyngeal carcinoma;Pheochromocytoma;Pineal parenchymal tumor of intermediate differentiation;Pineoblastoma and supratentorial primitive neuroectodermal tumor;Pituitary tumor;Plasma Celtic neoplasm / multiple myeloma;Pleuropulmonary blastoma;Primary central nervous system lymphoma;Prostate cancer;Rectal cancer;Renal cell (kidney) cancer;Renal pelvis and ureter, transitional cell carcinoma;Respiratory system cancer involving the NUT gene on chromosome 15;Retinoblastoma;Rhabdomyosarcoma;Salivary gland carcinoma;Sarcoma, Ewing's pharmacokinetics of tumor Milli;Sarcoma, Kaposi;Sarcoma, soft tissue;Sarcoma, uterine;Sezary syndrome;Skin cancer (non-melanoma);Skin cancer (melanoma);Skin cancer, Merkel cell carcinoma;Small cell lung cancer;Small intestinal cancer;Soft tissue sarcoma;Squamous cell carcinoma, cervical squamous cell carcinoma with occult primary, metastatic;Stomach (Gastric) cancer;Supratentorial primitive neuroectodermal tumor;T-cell lymphoma, cutaneous;Testicular cancer;Thymoma and thymic carcinoma;Thyroid cancer;Transitional cell carcinoma of the renal pelvis and ureter;Chorionic tumor, gestational;Urethral cancer;Uterine cancer, endometriotic;Uterine sarcoma;Vaginal cancer;Vulvar cancer;Waldenstrom's macroglobulinemia, and Wilms' tumor.;

[0219] In one embodiment, the invention provides a method for treating cancer metastasis comprising treating a subject with a complementary cancer therapy, such as surgery, chemotherapy, chemotherapeutic agents, radiation therapy, or hormonal therapy, or a combination thereof, prior to, simultaneously with, or following treatment with a composition of the invention.

[0220] Chemotherapeutic agents include cytotoxic agents (e.g., 5-fluorouracil, cisplatin, carboplatin, methotrexate, daunorubicin, doxorubicin, vincristine, vinblastine, oxorubicin, carmustine (BCNU), lomustine (CCNU), cytarabine USP, cyclophosphamide, estramucin sodium phosphate, altretamine, hydroxyurea, ifosfamide, procarbazine, mitomycin, busulfan, cyclophosphamide, mitoxantrone, carboplatin, cisplatin, interferon alfa, α-2a recombinant, paclitaxel, teniposide, and streptozocine), cytotoxic alkylating agents (e.g., busulfan, chlorambucil, cyclophosphamide, melphalan, or ethylsulfonic acid), alkylating agents (e.g., asar, AZQ, BCNU, busulfan, bisulfan, carboxyphthalatoplatinum, CBDCA, CCNU, CHIP, chlorambucil, chlorozotocin, cisplatinum, clomesone, cyanomorpholinodoxorubicin, cyclodisone, cyclophosphamide, dianhydrogalactitol, fluorodopan, hepsulfame, hycanthone, ifosfamide, melphalan, methyl CCNU, mitomycin C, mitozolamide, nitrogen mustard, PCNU, piperazine, piperazinedione, pipobroman, porfiromycin, spirohydantoin mustard, streptozotocin, teroxylon, tetraplatin, thiotepa, triethylenemelamine, uracil nitrogen mustard, and Yoshi-864), antimitotic agents (e.g., allocolchicine, halichondrin M, colchicine, colchicine derivatives, dolastatin 10, maytansine, , rhizoxin, paclitaxel derivatives, paclitaxel, thiocolchicine, tritylcysteine, vinblastine sulfate, and vincristine sulfate), plant alkaloids (e.g., actinomycin D, bleomycin, L-asparaginase, idabicin, vinblastine sulfate, vincristine sulfate, mithramycin, mitomycin, daunorubicin, VP-16-213, VM-26, navelbine, and taxotere), biological agents (e.g., alpha interferon, BCG, G-CSF, GM-CSF, and interleukin-2),These include topoisomerase I inhibitors (e.g., camptothecin, camptothecin derivatives, and morpholinodoxorubicin), topoisomerase II inhibitors (e.g., mitoxantrone, amonafide, m-AMSA, anthrapyrazole derivatives, pyrazoloacridine, bisantrene HCL, daunorubicin, deoxydoxorubicin, menogaril, N,N-dibenzyldaunomycin, oxantrazole, rubidazone, VM-26, and VP-16), and synthetics (e.g., hydroxyurea, procarbazine, o,p'-DDD, dacarbazine, CCNU, BCNU, cis-diamminedichloroplatinum, mitoxantrone, CBDCA, levamisole, hexamethylmelamine, all-trans retinoic acid, gliadel, and porfimer sodium).

[0221] Antiproliferative agents are compounds that reduce cell proliferation.Antiproliferative agents include alkylating agents, antimetabolites, enzymes, biological response modifiers, other agents, hormones and antagonists, androgen inhibitors (e.g., flutamide and leuprolide acetate), antiestrogens (e.g., tamoxifen citrate and its analogs, toremifene, droloxifene, and roloxifene), and additional examples of specific antiproliferative agents include, but are not limited to, levamisole, gallium nitrate, granisetron, sargramostim strontium chloride-89, filgrastim, pilocarpine, dextrazoxane, and ondansetron.

[0222] The compounds of the present invention can be administered alone or in combination with other antitumor agents, including cytotoxic / antitumor agents and antiangiogenic agents. Cytotoxic / antitumor agents are defined as agents that attack and kill cancer cells. Some cytotoxic / antitumor agents are alkylating agents that alkylate the genetic material of tumor cells, such as cisplatin, cyclophosphamide, nitrogen mustard, trimethylene thiophosphoramide, carmustine, busulfan, chlorambucil, verstine, uracil mustard, chromafazine, and dacarbazine. Other cytotoxic / antitumor agents are tumor cell antimetabolites, such as cytosine arabinoside, fluorouracil, methotrexate, mercaptopurine, azathioprime, and procarbazine. Other cytotoxic / antitumor agents are antibiotics, such as doxorubicin, bleomycin, dactinomycin, daunorubicin, mithramycin, mitomycin, mitomycin C, and daunomycin. There are numerous liposomal formulations commercially available for these compounds. Still other cytotoxic / antitumor agents are the mitotic inhibitors (vinca alkaloids). These include vincristine, vinblastine, and etoposide. Other cytotoxic / antitumor agents include taxol and its derivatives, L-asparaginase, antitumor antibodies, dacarbazine, azacytidine, amsacrine, melphalan, VM-26, ifosfamide, mitoxantrone, and vindesine.

[0223] Antiangiogenic agents are well known to those skilled in the art. Antiangiogenic agents suitable for use in the methods and compositions of the present invention include anti-VEGF antibodies, including humanized and chimeric antibodies, anti-VEGF aptamers, and antisense oligonucleotides. Other known inhibitors of angiogenesis include angiostatin, endostatin, interferon, interleukin 1 (including alpha and beta) interleukin 12, retinoic acid, and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and -2). Small molecules that contain topoisomerase, such as razoxane, a topoisomerase II inhibitor with antiangiogenic activity, can also be used.

[0224] Other anti-cancer drugs that can be used in combination with the compositions of the present invention include, but are not limited to, acivicin, aclarubicin, acodazole hydrochloride, acronine, adozelesin, aldesleukin, altretamine, ambomycin, amethanthrone acetate, aminoglutethimide, amsacrine, anastrozole, anthramycin, asparaginase, asperlin, azacytidine, azetepa, azotomycin, batimastat, benzodepa, bicalutamide, bisantrene hydrochloride, bisnafide dimesylate, bizeresin, bleomycin sulfate, Brequinar sodium, bropirimine, busulfan, cactinomycin, calsterone, caracemide, carbetimer, carboplatin, carmustine, carubicin hydrochloride, carzelesin, cedefingol, chlorambucil, ciloremycin, cisplatin, cladribine, crisnatol mesylate, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin hydrochloride, decitabine, dexorumaplatin, desaguanine, desaguanine mesylate, diaziquone, docetaxel, doxorubicin, doxorubicin hydrochloride, droloxifene , droloxifene citrate, dromostanolone propionate, duazomycin, edatrexate, eflornithine hydrochloride, elsamitrucin, enloplatin, enpromate, epipropizine, epirubicin hydrochloride, elbrozole, esorubicin hydrochloride, estramustine, estramustine phosphate sodium, etanidazole, etoposide, etoposide phosphate, etoprine, fadrozole hydrochloride, fazarabine, fenretinide, floxuridine, fludarabine phosphate, fluorouracil, fluorocitabine, fosquito netil, Don, fostriecin sodium, gemcitabine, gemcitabine hydrochloride, hydroxyurea, idarubicin hydrochloride, ifosfamide, irmofosine, interleukin II (including recombinant interleukin II, or rIL2), interferon alpha-2a, interferon alpha-2b, interferon alpha-n1, interferon alpha-n3, interferon beta-Ia, interferon gamma-Ib, iproplatin, irinotecan hydrochloride, lanreotide acetate, letrozole, leuprolide acetate, liarozole hydrochloride,Lometrexol sodium, lomustine, losoxantrone hydrochloride, masoprocol, maytansine, mechlorethamine hydrochloride, megestrol acetate, melengestrol acetate, melphalan, menogaril, mercaptopurine, methotrexate, methotrexate sodium, metoprine, meturedepa, mitindomide, mitocalcin, mitochromine, mitogillin, mitomarcine, mitomycin, mitospel, mitotane, mitoxantrone hydrochloride, mycophenolic acid, nocoda zole, nogalamycin, ormaplatin, oxisuran, paclitaxel, pegaspargase, periomycin, pentamustine, peplomycin sulfate, perfosfamide, pipobroman, piposulfan, piroxantrone hydrochloride, plicamycin, promestane, porfimer sodium, porfiromycin, prednimustine, procarbazine hydrochloride, puromycin, puromycin hydrochloride, pyrazofurin, ribopurin, rogletimide, safingol, safingol, Fingol hydrochloride, semustine, simtrazene, sparphosate sodium, sparsomycin, spirogermanium hydrochloride, spiromustine, spiroplatin, streptonigrin, streptozocin, sulofenur, tallysomycin, tecogalan sodium, tegafur, teroxantrone hydrochloride, temoporfin, teniposide, teroxylon, testolactone, thiamiprine, thioguanine, thiotepa, tiazofurin, tirapazamine, toremifene citrate, acetate Trestron, triciribine phosphate, trimetrexate, trimetrexate glucuronate, triptorelin, tuburozole hydrochloride, uracil mustard, uredepa, vapreotide, verteporfin, vinblastine sulfate, vincristine sulfate, vindesine, vindesine sulfate, vinepidine sulfate, vinglicinate sulfate, vinleurosine sulfate, vinorelbine tartrate, vinrocidine sulfate, vinzolidine sulfate, vorozole, zeniplatin, zinostatin, zorubicin hydrochloride.Other anticancer drugs include, but are not limited to: 20-epi-1,25 dihydroxyvitamin D3, 5-ethynyluracil, abiraterone, aclarubicin, acylfulvene, adecipenol, adzelesin, aldesleukin, ALL-TK antagonist, altretamine, ambamustine, amidox, amifostine,Aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole, andrographolide, angiogenesis inhibitors, antagonist D, antagonist G, antarelix, anti-dorsalized morphogenetic protein-1, antiandrogen, prostate cancer, antiestrogens, antineoplastic agents, antisense oligonucleotides, aphidicolin glycinate, apoptotic gene regulators, apoptotic regulators, apurinic acid, ara-CDP-DL-PTBA, arginine deaminase, asulaculin, atamestane, atrimustine, axinastatin 1, axinastatin 2, axinastatin 3, azasetron, azatoxin, Azatyrosine, Baccatin III derivatives, Balanol, Batimastat, BCR / ABL antagonists, Benzochlorin, Benzoylstaurosporine, Beta-lactam derivatives, Beta-arretin, Beta-clamycin B, Betulinic acid, bFGF inhibitors, Bicalutamide, Bisantrene, Bisaziridinylspermine, Bisnafide, Bistraten A, Bizelesin, Brefrate, Bropirimine, Budotitanium, Buthionine sulfoximine, Calcipotriol, Calphostin C, Camptothecin derivatives, Canarypox IL-2, Capecitabine, Carboxamido-amino-triazole, Carboxamidotriazole, CaRest M3, CARN700, cartilage derived inhibitor, carzelesin, casein kinase inhibitor (ICOS), castanospermine, cecropin B, cetrorelix, chlorine, chloroquinoxaline sulfonamide, cicaprost, cis-porphyrin, cladribine, clomiphene analogue, clotrimazole, colismycin A, colismycin B, combretastatin A4, combretastatin analogue, conagenin, crambecidin 816, cristathol, cryptophycin 8, cryptophycin A derivatives, curacin A, cyclopentaquinone, cycloplatam, cypemycin, cytarabine ocphosphate, cytolytic factors, cytostatin, dacliximab, decitabine, dehydrodimethine B, deslorelin, dexamethasone, dexphosphamide, dexrazoxane, dexverapamil, diaziquone, didemnin B, didox, diethylnorspermine, dihydro-5-azacytidine, dihydrotaxol, 9-, dioxamycin, diphenylspiromustine,Docetaxel, docosanol, dolasetron, doxifluridine, droloxifene, dronabinol, duocarmycin SA, ebselen, ecomustine, edelfosine, edrecolomab, eflornithine, elemene, emiteflu, epirubicin, epristeride, estramustine analogues, estrogen agonists, estrogen antagonists, etanidazole, etoposide phosphate, exemestane, fadrozole, fazarabine, fenretinide, filgrastim, finasteride, flavopiridol, frezelastine, fluas Teron, fludarabine, fluorodaunornithine hydrochloride, forfenimex, formestane, fostriecin, fotemustine, gadolinium texaphyrin, gallium nitrate, gallocitabine, ganirelix, gelatinase inhibitors, gemcitabine, glutathione inhibitors, hepsulfame, heregulin, hexamethylene bisacetamide, hypericin, ibandronic acid, idarubicin, idoxifene, idramantone, ilmofosine, ilomastat, imidazoacridone, imiquimod, immunostimulating peptides, insulin-like growth factor-1 receptor inhibitors, interleukin-1, -feron agonist, interferon, interleukin, iobenguan, iododoxorubicin, ipomeanol, 4-, iroplact, irsogladine, isobengazole, isohomohalichondrin B, itasetron, jasplakinolide, kahalalide F, lamellarin-N triacetate, lanreotide, leinamycin, lenograstim, lentinan sulfate, leptolstatin, letrozole, leukemia inhibitory factor, leukocyte alpha interferon, leuprolide + estrogen + progesterone, leuprorelin, Levamisole, liarozole, linear polyamine analogues, lipophilic diglycosylated peptides, lipophilic platinum compounds, lysoclinamide 7, lobaplatin, lombricin, lometrexol, lonidamine, losoxantrone, lovastatin, loxoribine, lutecan, lutetium texaphyrin, lysofylline, lytic peptides, maytansine, mannostatin A, marimastat, masoprocol, maspin, matrilysin inhibitors, matrix metalloproteinase inhibitors, menogaril, mervalone, meterelin, methioninase, metoclopramide, MIF inhibitors,Mifepristone, Miltefosine, Millimostim, Mismatched double-stranded RNA, Mitoguazone, Mitolactol, Mitomycin analogue, Mitonafide, Mitotoxin fibroblast growth factor-saporin, Mitoxantrone, Mofalotene, Molgramostim, Monoclonal antibodies, Human chorionic gonadotropin, Monophoryl lipid A+ Myobacterium cell wall sk, Mopidamol, Multidrug resistance gene inhibitors, Multiple tumor suppressors 1-based therapy, Mustard anticancer drugs, Mycaperoxide B, Mycobacterial cell wall extract, Myriaporone, N-acetylglucosamine, N-substituted benzaldehyde Zamide, nafarelin, nagressip, naloxone + pentazocine, napavine, naphterpine, nartograstim, nedaplatin, nemorubicin, neridronic acid, neutral endopeptidase, nilutamide, nisamycin, nitric oxide regulators, nitroxide antioxidants, nitrulline, O6-benzylguanine, octreotide, oxenone, oligonucleotides, onapristone, ondansetron, ondansetron, oracin, oral cytokine inducers, ormaplatin, osaterone, oxaliplatin, oxaunomycin, paclitaxel, paclitaxel Ritaxel analogues, paclitaxel derivatives, parauamine, palmitoyl rhizoxin, pamidronic acid, panaxytriol, panomyphen, parabactin, pazelliptin, pegaspargase, perdecin, pentosan polysulfate sodium, pentostatin, pentrozole, perflubron, perphosphamide, perillyl alcohol, phenazinomycin, phenylacetate, phosphatase inhibitors, picibanil, pilocarpine hydrochloride, pirarubicin, piritrexim, prasetin A, prasetin B, plasminogen activator inhibitors, Platinum complexes, platinum compounds, platinum triamine complexes, porfimer sodium, porfiromycin, prednisone, propyl bis-acridone, prostaglandin J2, proteasome inhibitors, protein A-based immunomodulators, protein kinase C inhibitors, protein kinase C inhibitors, microalgae, protein tyrosine phosphatase inhibitors, purine nucleoside phosphorylase inhibitors, purpurins, pyrazoloacridines, pyridoxylated hemoglobin polyoxyethylene conjugates, raf antagonists, raltitrexed, ramosetron,ras farnesyl protein transferase inhibitors, ras inhibitors, ras-GAP inhibitors, demethylated reterliptin, rhenium Re186 etidronate, rhizoxin, ribozyme, RII retinamide, logretimide, rohitucine, romultide, roquinimex, rubiginone B1, Ruboxil, Safingol, Santopine, SarCNU, Sarcophytol A, Sargramostim, Sdi1 mimetic, Semustine, Senescence derived inhibitor 1, Sense oligonucleotide, Signal transduction inhibitor, Signal transduction modulator, Single chain antigen binding protein, Schizofuran, Sobuzoxane, Borocaptate sodium, Sodium phenylacetate, Sorbrol, Somatomedin binding protein, Sonermin, Sparfosic acid, Spicamycin D, Spiromustine, Splenopentin, Spongestatin 1, Squalamine, Stem cell inhibitor, Stem cell division inhibitor, Stipiamide, Stromelysin inhibitor, Sulfinosine, Superactive intestinal peptide antagonist, Slajista, Suramin, Swainsonine, Synthetic glycosaminoglycan, Talimustine, Tamoxifen methiodide, Tauromustine, Tazarotene, Tecogalan sodium, Tegafur, Terlapyrylium, Telomerase inhibitor, Temoporfin, Te Mozolomide, teniposide, tetrachlorodecaoxide, tetrazomine, thaliblastine, thiocoraline, thrombopoietin, thrombopoietin mimetics, thymalfasin, thymopoietin receptor agonist, thymotrinan, thyrotropin, tin ethyl etiopurpurin, tirapazamine, titanocene dichloride, topsentin, toremifene, totipotent stem cell factor, translation inhibitors, tretinoin, triacetyluridine, triciribine, trimetrexor In one embodiment, the anticancer agent is 5-fluorouracil, taxol, or leucovorin.

[0225] In vitro and ex vivo generation of synthetic antibodies In one embodiment, a synthetic antibody (e.g., a DMAb, ScFv fragment, or DBiTE) is generated in vitro or ex vivo. For example, in one embodiment, a nucleic acid encoding a synthetic antibody (e.g., a DMAb, ScFv fragment, or DBiTE) can be introduced and expressed in an in vitro or ex vivo cell. Methods for introducing and expressing genes into cells are known in the art. In the context of an expression vector, the vector can be easily introduced into a host cell, such as a mammalian, bacterial, yeast, or insect cell, by any method in the art. For example, the expression vector can be introduced into a host cell by physical, chemical, or biological means.

[0226] Physical methods for introducing polynucleotides into host cells include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, etc. Methods for producing cells containing vectors and / or exogenous nucleic acids are well known in the art. See, for example, Sambrook et al. (2012, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York). A preferred method for introducing polynucleotides into host cells is calcium phosphate transfection.

[0227] Biological methods for introducing target polynucleotide into host cell include the use of DNA vector and RNA vector.Viral vector, and especially retroviral vector, have become the most widely used method for inserting genes into mammalian, for example human cells.Other viral vectors can be derived from lentivirus, poxvirus, herpes simplex virus I, adenovirus and adeno-associated virus, etc.See, for example, U.S. Patent No. 5,350,674 and 5,585,362.

[0228] Chemical means for introducing polynucleotides into host cells include macromolecular complexes, nanocapsules, microspheres, beads, and colloidal dispersion systems such as lipid systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. An exemplary colloidal system for use as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle).

[0229] In the case where a non-viral delivery system is utilized, an exemplary delivery vehicle is a liposome. The use of lipid formulations is contemplated for the introduction of nucleic acids into host cells (in vitro, ex vivo, or in vivo). In another embodiment, the nucleic acid may be associated with a lipid. The nucleic acid associated with a lipid may be encapsulated in the aqueous interior of a liposome, dispersed within the lipid bilayer of a liposome, bound to a liposome via a linking molecule associated with both the liposome and the oligonucleotide, entrapped in a liposome, complexed with a liposome, dispersed in a solution containing lipids, mixed with lipids, combined with lipids, contained as a suspension in lipids, contained in micelles, or complexed with micelles, or otherwise associated with lipids. The lipid, lipid / DNA, or lipid / expression vector associated compositions are not limited to any particular structure in solution. For example, they may exist in a bilayer structure as micelles, or have a "collapsed" structure. They may also simply be dispersed in solution and may form aggregates that are not uniform in size or shape. Lipids are fatty substances that can be naturally occurring or synthetic. For example, lipids include the lipid droplets that occur naturally in the cytoplasm, as well as the class of compounds that contain long-chain aliphatic hydrocarbons and their derivatives, such as fatty acids, alcohols, amines, aminoalcohols, and aldehydes. EXAMPLES

[0230] The present invention is further illustrated in the following examples. It should be understood that these examples, while showing preferred embodiments of the present invention, are given by way of illustration only. From the above discussion and these examples, those skilled in the art can ascertain the essential features of the present invention, and can make various changes and modifications of the present invention to suit various uses and conditions without departing from the spirit and scope thereof. Thus, in addition to those shown and described herein, various modifications of the present invention will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

[0231] Example 1 The work presented herein demonstrates the development of DNA-encoded bispecific T cell engagers (DBiTEs) targeting CD19, BCMA, CD33, FAP, FSHR, EGFR, PSMA, or CD123. The DBiTE constructs are expressed at high levels in vivo. Figure 1 shows the expression of BCMADBiTEs, CD33DBiTEs, and CD123DBiTEs. Figure 2 shows the expression of EGFRvIIIDBiTEs, FSHRDBiTEs, PSMADBiTEs, and CD19DBiTEs. These novel DBiTEs represent new tools for the immunotherapy of cancer.

[0232] Figures 3-5 provide data showing that CD19DBiTE functions for both B cell depletion and T cell activation. PBMCs from three independent donors were cultured in triplicate for 5 hours in the presence of 5 μl of CD19DBiTE or control DBiTE (EGFRvIIIDBiTE) supernatant. After incubation, cells were stained for B cell and T cell markers to determine potential cytolytic activity for early activation of B cells (CD19+ cells) and T cells. Figure 4 provides data showing that all three donors showed depletion of B cells (CD19+ cells in the PBMC mixture) in the presence of CD19DBiTE but not in the presence of control DBiTE. Figure 5 provides data showing that all three donors showed an increase in the early activation marker CD69 in T cells in the presence of CD19DBiTE but not in the presence of control DBiTE.

[0233] Furthermore, experiments were performed to demonstrate the cytotoxicity of BCMADBiTEs. BCMADBiTE or CD33DBiTE supernatants were incubated for 5 h with RPMI8226 cell lines and derived T cells from one donor at tumor-to-T cell ratios of 1:0, 1:3, and 1:7 (10,000 tumor cells per well). Upon 5 h of incubation, BCMAdBiTEs were able to lyse cells at ratios of 1:1, 1:3, and 1:7, but not in the absence of T cells, and no killing occurred under any condition in the presence of CD33DBiTEs.

[0234] Example 2 The work presented herein demonstrates the development of DNA monoclonal antibodies and BiTEs targeting HER2 (HER2DMAb and HER2DBiTE) and their use as therapeutics for the treatment of ovarian and breast cancer. Both DMAb and DBiTE constructs are expressed at high levels in vitro and in vivo for approximately 4 months. HER2DMAb binds to HER2 and induces HER2 signaling blockade and antibody-dependent cellular cytotoxicity. HER2DBiTE effectively induces T-cell cytotoxicity against HER2+ tumor cells. These novel DNA technologies represent new tools for further research into the immunotherapy of cancer.

[0235] Materials and methods are described herein. Animals and cell lines C57Bl / 6 and Nu / J mice were purchased from Jackson labs. NSG mice were purchased from the Wistar Institute Animal Facility.

[0236] OVCAR3, SKOV3, and Brpkp110 cells were provided by JR Corejo-Garcia (Department of Immunology, Moffitt Cancer Center, FL). TOV-21G and RNG1 were provided by R. Zhang (The Wistar Institute). OVCAR3 tumors were generated by injecting 3 million cells in PBS / Matrigel (50 / 50) into the flank as previously described (Perales-Puchalt et al., 2017, Clin Cancer Res, 23(2):441-53). RD and 293T cells were purchased from ATCC.

[0237] Mice were injected with 100 μg of DNA resuspended in 80 μl of water with 200 IU / ml hyaluronidase (Sigma) into the tibialis anterior muscle (40 μl per leg) and treated by electroporation in a CELLECTRA device 1 min after injection.

[0238] Design of HER2DMAb and HER2DBiTE HER2DMAb was designed and generated, encoding the codon-optimized sequences of the heavy and light chains of the anti-HER2 monoclonal antibody pertuzumab. Both antibody chains were positioned with sequences separated by P2A and furin cleavage sites. An IgE leader sequence was substituted for the original leader sequence. HER2DBiTE was designed by encoding the codon-optimized scFv of HER2DMAb followed by the scFv of the OKT3 anti-human CD3 antibody and adding the IgE leader sequence. Both constructs were subcloned into a modified pVAX1 expression vector (Figure 6A and Figure 11A).

[0239] The empty modified pVAX1 plasmid was used as a negative control.

[0240] In vitro DMAb expression One million 293T cells were seeded into each chamber of a 6-well plate. The next day, cells were transfected with 1 μg of HER2DMAb plasmid using Lipofectamin2000 (Invitrogen). Supernatants were harvested 48 hours after transfection.

[0241] Flow cytometry Anti-human antibodies used were directly fluorochrome conjugated. HER2 (24D2), CD45 (HI30), CD3 (HIT3A), CD69 (FN50), PD-1 (EH12.2H7), and secondary anti-human IgG APC (polyclonal) were obtained from Biolegend. Live / dead exclusion was performed with 7AAD (Invitrogen) and Annexin V (Biolegend).

[0242] Immunoblotting Protein extraction, denaturation and Western blotting were performed as previously described (Perales-Puchalt et al., 2017, Clin Cancer Res, 23(2):441-53). Membranes were blotted with polyclonal anti-human IgG(H+L) (Bethyl) and anti-β-actin (a5441, Sigma-Aldrich). Images were captured on an ImageQuantLAS4000 (GE Healthcare Life Sciences).

[0243] For signaling blockade experiments, 200,000 OVCAR3 cells were seeded in 6-well plates and starved overnight in serum-free medium. The following day, 10 μg of purified HER2DMAb or PBS was added to appropriate wells for 1 h, followed by 10 ng / ml HRG (Peprotech) for 30 min.

[0244] HER2 binding ELISA ELISA plates were coated with 1 μg / ml human HER2 recombinant protein (abcam) overnight at 4°C. Blocking was performed with PBST-10%FBS for 1 h. Different dilutions of serum from HER2DMAb expressing mice or controls (electroporated with empty pVax plasmid) were used as primary antibodies and incubation was performed for 1 h at room temperature. The secondary antibody was goat anti-human IgG Fc HRP conjugate (Bethyl). After 1 h incubation, development was performed with SIGMAFAST OPD (Sigma Aldrich) and read at 450 nm.

[0245] DMAb quantitative ELISA ELISA plates were coated with 1 μg / ml goat anti-human IgG-Fc fragment antibody (Bethyl) overnight at 4°C. The next day they were blocked with PBST-10% FBS for 1 h at room temperature, washed, incubated with samples diluted in PBST-1% FBS for 1 h at room temperature, washed, and incubated with HRP-conjugated goat anti-human kappa light chain antibody (Bethyl) at room temperature. After 1 h of incubation, they were developed with SIGMAFAST OPD (Sigma Aldrich) and read at 450 nm. A standard curve was generated using purified human IgG / kappa (Bethyl).

[0246] CD3 and HER2 binding ELISA (DBiTE) ELISA plates were coated with 1 μg / ml human HER2 recombinant protein (abcam) or human CD3 epsilon (Acrobiosystems) overnight at 4°C. They were blocked with PBST-10% FBS for 1 h. Serum from HER2DBiTE expressing mice or controls (electroporated with empty pVax plasmid) were used as primary antibodies. They were incubated for 1 h at room temperature. The secondary antibody was goat anti-human IgG H+L HRP conjugate (Bethyl). After 1 h incubation, plates were developed with SIGMAFAST OPD (Sigma Aldrich) and read at 450 nm.

[0247] Detection of anti-HER2DMAb and HER2DBiTE antibodies ELISA plates were coated with 1 μg / ml purified HER2DMAb or HER2DBiTE overnight at 4° C. The next day, plates were blocked with PBST-10% FBS for 1 h at room temperature, washed, incubated with samples diluted in PBST-1% FBS for 1 h at room temperature, washed, and incubated with HRP-conjugated goat anti-mouse IgG antibody (Abcam) at room temperature. After 1 h incubation, plates were developed with SIGMAFAST OPD (Sigma Aldrich).

[0248] Detection of T cell activation and apoptosis by HER2DBiTE 96-well plates were seeded with 5,000 OVCAR3 cells overnight at 4°C. The next day, serum from HER2DBiTE-expressing mice or pVax control (1:20 dilution in PBS, 100 μl) and 50,000 T cells were added and plates were incubated at 37°C. After 24 hours, supernatants were taken for IFNγ ELISA and fresh supernatants were added. After 72 hours, flow cytometry was performed to measure T cell apoptosis and activation (CD3, CD69, PD-1, Annexin V). For cell counts, 5,000 OVCAR3 cells were seeded with 100,000 T cells and viable T cell counts were counted using the dead cell exclusion dye Trypan Blue (ThermoFisher) and a Countess II automated cell counter (ThermoFisher).

[0249] Interferon gamma ELISA Determination of human interferon gamma from the supernatants was performed using the Human IFNg ELISA MAX (Biolegend) according to the manufacturer's instructions.

[0250] In vitro cytotoxicity 10,000 OVCAR3 cells per well were seeded in 96-well plates and after 18 h were co-incubated with 500,000 human PBMCs from healthy donors (provided by the University of Pennsylvania Human Immunology Core) or 500,000 splenocytes from nude mice in the presence or absence of HER2DMAb for 4 h. After 4 h, supernatants were collected, cells were trypsinized, stained for 7AAD (Invitrogen), Annexin V (Biolegend) and anti-human CD45 (Biolegend), and flow cytometry-based cytotoxicity assays were performed as previously described (Perales-Puchalt et al., 2017, Clin Cancer Res, 23(2):441-53). Alternatively, luciferase-expressing OVCAR3 or MDA-MB-231 were used and luciferase expression was measured after co-culture. For BiTE killing assays, 10,000 OVCAR3-luciferase cells were incubated with different ratios of T cells for 5 h, washed with PBS, lysed, and luciferase expression was measured.

[0251] Antibody-dependent cell phagocytosis Macrophages were differentiated from human monocytes by seeding 1 million monocytes per T25 with 50 ng / ml human M-CSF (Peprotech). Medium with cytokines was changed on days 3 and 6. On day 6, macrophages were trypsinized, stained with cell tracing violet (Invitrogen) according to the manufacturer's instructions, seeded at 50,000 / well in 96-well plates, and left them overnight with 20 ng / ml M-CSF. On day 7, OVCAR3 cells were stained with CFSE (Invitrogen), and 10,000 OVCAR3 cells were seeded on the wells together with macrophages with HER2DMAb or pVax serum. After 24 h, cells were trypsinized and flow cytometry was performed. Phagocytosis was measured as double-positive stained cells.

[0252] Immunofluorescence Mouse tumors were frozen in OCT (TissueTek) and frozen sections were cut. Slides were then fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100 in PBS. Sections were blocked using 5% normal goat serum and subsequently stained with HER2DMAb antibody and anti-human AF488 conjugated secondary (Invitrogen).

[0253] Slides were viewed using a Leica TCS SP5 II confocal microscope and LAS software (Leica).

[0254] statistics Differences between the means of experimental groups were calculated using two-tailed unpaired Student's t-test or one-way ANOVA, where two categorical variables were measured. Repeated measurements were analyzed using two-way ANOVA. Error bars represent the standard deviation of the mean. Survival rates were compared using the log-rank test. All statistical analyses were performed using Graph Pad Prism 7.0. p<0.05 was considered statistically significant.

[0255] The results of the experiments are described here.

[0256] Design and expression of a HER2 DNA-encoded monoclonal antibody (DMAb) DNA-encoded antibodies (DMAbs) have a series of advantages over traditional protein antibodies. First, DNA is more stable than proteins. This higher stability eliminates the need to rigorously maintain the antibody chains in a chilled state, which increases the cost of treatment and limits the product half-life (Hernandez et al., 2018, Am J Manag Care, 24(2):109-12). Furthermore, intracellular delivery of these antibody-encoding DNA plasmids achieves stable plasma antibody concentrations over significant periods of time, limiting the need for multiple dosing, providing a novel tool for the immunotherapy of cancer.

[0257] HER2DMAb was generated by encoding the codon and RNA optimized sequences for the heavy and light chains of pertuzumab into the pVAX1 plasmid expression vector (Figure 6A). These sequences were preceded by an IgE signal peptide, and the heavy and light chains were separated by P2A and a furin cleavage site. Antibody expression was tested in vitro by transfecting 293T cells with DNA encoding HER2DMAb or an unrelated protein. After 48 h, supernatants were collected and Western blotted. Bands corresponding to the heavy and light antibody chains were identified in HER2DMAb-transfected 293T supernatants, but not in the unrelated protein control (Figure 6B). ELISA was used to determine the amount of human IgG, and it was observed that HER2DMAb was expressed by 293T at 5-6 μg / ml, which was verified using RD cells (Figure 7A).

[0258] After confirming in vitro expression, HER2DMAb expression was confirmed in vivo. 200 μg of HER2DMAb or empty vector was injected into the tibialis anterior muscle of mice, followed by adaptive electroporation using the CELLECTRA3P system (Tebas et al., 2017, N Engl J Med, Epub ahead of print). Similar to the in vitro system, the presence of human IgG was identified in serum from HER2DMAb-injected mice, but not in controls (Figure 6C), and expression levels in mouse serum reached 50 μg / ml, averaging approximately 25 μg / ml (Figure 6D).

[0259] Next, the ability of DNA-encoded human IgG to bind human HER2 was tested. Plates were coated with human HER2 protein and incubated with serum from HER2DMAb-treated mice or control serum. HER2DMAb from mouse serum bound to human HER2 in a dose-dependent manner (Figure 6E). To confirm HER2 binding when the protein is present on the cell surface, human HER2 was overexpressed in the mouse cell line Brpkp110. HER2DMAb bound to human HER2 by flow cytometry only when ectopically expressed (Figure 6F).

[0260] HER2 is expressed in human ovarian cancer cell lines. Pertuzumab, unlike trastuzumab, does not require HER2 overexpression in tumor cells for its antitumor activity (Agus et al., 2002, Cancer Cell, 2(2):127-37). In ovarian cancer, pertuzumab has shown a trend towards increased progression-free survival in combination treatment with gemcitabine and paclitaxel (Kurzeder et al., 2016, J Clin Oncol, 34(21):2516-25). HER2 is overexpressed (histological score 2+ / 3+) in approximately 11.4% of ovarian cancers (Bookman et al., 2003, J Clin Oncol, 21(2):283-90). To determine whether HER2 is also expressed in ovarian cancer cell lines, flow cytometry was performed using the commercially available 24D2 antibody (Figure 8A). Binding of HER2DMAb was verified by performing flow cytometry on these same cells (Figure 8B). To further validate the in vivo expression and potential targeting of ovarian cancer cell lines using HER2DMAb, OVCAR3 tumors were generated in mice and immunofluorescence was performed on tumor cryosections. Positive binding was seen using serum from HER2DMAb-transfected mice, but not control serum, confirming the in vivo expression of HER2 and binding of HER2DMAb (Figure 8C).

[0261] HER2DMAb mediates HER2 signaling blockade and antibody-dependent cellular cytotoxicity. Different mechanisms are responsible for the antitumor effects of anticancer antibodies. Pertuzumab acts by preventing HER2 heterodimerization and agonist-mediated signaling (Franklin et al., 2004, Cancer Cell, 5(4):317-28). As expected, HER2DMAb prevented HER2-HER3 agonist heregulin-induced (HRG-induced) signaling in OVCAR3 cells, as evidenced by reduced Akt phosphorylation compared to vehicle control (Figure 9A).

[0262] Another mechanism by which MAbs have antitumor activity is through antibody-dependent cellular cytotoxicity (ADCC). To study the ADCC potential of HER2DMAb, OVCAR3 cells were co-incubated with or without peripheral blood mononuclear cells (PBMCs) in the presence of serum from HER2DMAb or with serum from empty vector-treated mice. HER2DMAb serum effectively killed ovarian cancer cells in the presence of PBMCs but not in their absence. In addition, no killing was observed in control serum conditions (Figure 9B and Figure 7B) or against HER2 cell lines such as MDA-MB-231 (Figure 7C). Similarly, HER2dMAb exhibited antibody-dependent phagocytic activity (Figure 7D).

[0263] HER2DMAb delays cancer progression in vivo. To determine the antitumor effect of HER2DMAb in vivo, mice were challenged with the OVCAR-3 ovarian cancer cell line. Nude mice have no T cells but enhanced NK and macrophage activity, and their splenocytes could lyse OVCAR3 in vitro in the presence of HER2dMAb (Figure 7E). When tumors reached an average of 50 mm3, 100 μg of HER2DMAb or empty vector was delivered into muscle by EP. HER2DMAb-injected animals showed a significant delay in tumor growth, resulting in improved survival (Figure 9C). HER2DMAb antibody levels peaked at levels of approximately 20 μg / ml 2 weeks after DMAb injection and maintained levels of approximately 5–10 μg / ml over a month until the end of the experiment (Figure 9D). To validate the antitumor effect in an immune-competent host that better mimics clinical administration, tumors were generated using the murine human HER2 breast cancer cell line Brkpk110. This cell line was engineered to express HER2 levels similar to OVCAR3 (Figure 9E). Five days after tumor challenge, mice were treated with HER2DMAb or empty vector. HER2DMAb also delayed tumor progression in this aggressive model of breast cancer (Figure 9F).

[0264] When studying the kinetics of HER2dMAb, it was noted that there was a decrease in antibody expression over a period of almost 300 days. To investigate this phenomenon, the induction of antibodies against this human construct expressed in mice was evaluated. The development of anti-HER2dMAb antibodies was observed in serum after treatment with HER2dMAb (Figure 7F), which may contribute to its decline over time.

[0265] Generation, expression and cytotoxicity of HER2BiTEs Bispecific T cell engagers (BiTEs) possess two binding antibody fragments (scFv), one of which engages tumor antigens and the other activates by binding to T cells driving CD3 activation. Despite their high antitumor activity, these new tools have a major limitation due to their in vivo elimination half-life of approximately 2.1 hours, so BiTE therapy progresses slowly. This short half-life imposes on BiTE therapy that it should be administered by continuous intravenous infusion using an infusion pump for 4-8 weeks per cycle. Recent experiments with RNA-expressed BiTEs have shown expression for up to 6 days after IV infusion, indicating considerable progress (Stadler et al., 2017, Nat Med, 23(7):815-7).

[0266] An optimized HER2BiTE was generated by fusing the scFv of HER2DMAb with the scFv of the stimulatory antibody anti-CD3 (OKT3) (Figure 11A). The HER2BiTE was efficiently expressed in vivo upon injection and electroporation into mouse tibialis anterior muscle (Figure 11B). The new HER2DBiTE retained binding to HER2 and bound to CD3 (Figures 10A and 10B). Importantly, although the stimulation provided by UCHT1 has been reported to be capable of killing T cells, no increased apoptotic rate or difference in T cell numbers was observed when OKT3 cells were co-cultured with HER2DBiTE compared to the mere control in the presence of HER2+ cells (Figures 10C and 10D). To determine the function of the HER2DBiTE expressed in vivo, HER2+ ovarian cancer cells and T cells were cultured with serum from mice injected with HER2DBiTE or empty vector. Serum from mice after HER2DBiTE treatment demonstrated T cell activation (Figure 10E-G), as well as efficient dose-dependent cytotoxicity of OVCAR3 and CAOV3 cells. No cytotoxicity was observed upon incubation with serum from empty vector-treated mice or in the absence of T cells (Figure 11C and Figure 10H). Incubation of T cells with OVCAR3 at a 1:5 ratio with 5% serum (5 μl in 100 μl) from treated mice showed that DBiTE exhibited potent activity for approximately 4 months (Figure 11d). As with HER2DBiTE, generation of anti-HER2DBiTE antibodies was observed, which may be partially responsible for the circulating levels over time (Figure 10I). To determine DBiTE anti-tumor activity in vivo, NOD / SCID-γ (NSG) mice were challenged with OVCAR3. Mice were treated with a single dose of 200 μg of HER2DBiTE or empty vector 1 day after tumor implantation. Two weeks after tumor inoculation, tumors had grown to approximately 50 mm 3 When 10,000,000 PBMCs were injected intraperitoneally into each mouse, HER2DBiTE treatment significantly affected tumor progression (Figure 11E), with tumor regression or elimination observed in 8 of 10 tumors, whereas no tumor effect was observed in the control group (Figure 11F).

[0267] No in vivo effect of HER2DBiTE was observed in the absence of PBMCs (Figure 10J). HER2DBiTE delivered by a simple injection lasting only a few seconds was expressed in vivo for approximately 4 months and presented dramatic antitumor activity. Synthetic DNA delivery of BiTEs may alleviate the burden generated by the short half-life of BiTE therapy and provide new applications for this tool in cancer immunotherapy.

[0268] Taken together, the data demonstrate that DMAb can encode HER2DMAb and HER2DBiTE, allowing them to be durably expressed at high levels in vivo and drive potent antitumor activity. This approach provides a valuable new tool for the treatment of ovarian cancer as well as potentially other cancers.

[0269] Example 3 EGFRvIII-targeted DNA-encoded immune cell engager (DICE) generates in vivo expression of a bispecific antibody that induces T cell-mediated cytolytic activity against EGFRvIII-positive tumors and controls tumor growth in GBM mouse models. The development of bispecific antibodies targeting T cells and tumor-associated antigens (TAA) has expanded exponentially in recent years in both preclinical and clinical settings. In 2017, one bispecific antibody was approved to treat acute lymphoblastic leukemia. However, due to its low molecular weight, the serum half-life of the antibody is only about 4 hours. As a result, treatment requires continuous IV injections of the antibody over several days, which can extend to several weeks. Poor pharmacokinetic profiles, along with other difficulties related to manufacturing and molecular stability, present major challenges in the development of bispecific antibodies. To address these issues, an optimized synthetic DNA-encoded immune cell engager (DICE) designed to express bispecific antibodies in vivo was developed. Mice receiving a single dose of HER2-DICE show long-term in vivo expression of the bispecific antibody for over 120 days and T cell-mediated cytolytic activity against HER2-expressing ovarian cell lines. In the same study, HER2-DICE not only controlled tumor progression but also promoted tumor clearance in many animals in an ovarian cancer mouse model. Using a similar strategy, DICE was developed to target EGFRvIII, a TAA expressed in 30-50% of glioblastoma multiforme (GBM) patients. Supernatant samples from cells transfected with EGFRvIII-DICE in vitro demonstrated strong target-specific binding affinity for both EGFRvIII and CD3 and induced T cell-mediated cytolytic activity against GBM cell lines overexpressing EGFRvIII. Co-culture of target cells and primary human T cells in the presence of EGFRvIII-DICE supernatant stimulated robust T cell responses, demonstrating notable levels of IFNγ, TNFα, and CD107a in the cytotoxic T cell population. Finally, in a GBM mouse challenge model, treatment of EGFRvIII-DICE to NSG mice repopulated with human T cells resulted in control of tumor growth, which was not observed in the empty vector control group. These studies support that synthetic DNA delivery of bispecific antibodies generates potent and functional antibodies that can activate cytotoxic T cell function and may be investigated as an alternative approach to the development of bispecific antibodies for cancer immunotherapy.

[0270] It is understood that the foregoing detailed description and accompanying examples are merely illustrative and are not to be taken as limitations on the scope of the invention, which is defined solely by the appended claims and their equivalents.

[0271] Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications, including without limitation those related to the chemical structures, substitutes, derivatives, intermediates, compounds, compositions, formulations, or methods of use of the invention, may be made without departing from the spirit and scope thereof. Some aspects of the invention are described below. 1. A nucleic acid molecule encoding one or more synthetic DNA encoded bispecific immune cell engagers, said synthetic DNA encoded bispecific immune cell engagers comprising at least one antigen binding domain and at least one immune cell engaging domain. 2. The nucleic acid molecule of item 1, wherein the antigen-binding domain targets at least one antigen selected from the group consisting of CD19, B-cell maturation antigen (BCMA), CD33, fibroblast activation protein (FAP), follicle-stimulating hormone receptor (FSHR), epidermal growth factor receptor (EGFR), prostate-specific membrane antigen (PSMA), CD123, and human epidermal growth factor receptor 2 (Her2). 3. The nucleic acid molecule of item 1, wherein the immune cell engaging domain targets a cell selected from the group consisting of a T cell, an antigen-presenting cell, a natural killer (NK) cell, a neutrophil, and a macrophage. 4. The nucleic acid molecule of item 1, wherein the immune cell engaging domain targets at least one T cell-specific receptor molecule selected from the group consisting of CD3, T cell receptor (TCR), CD28, CD16, NKG2D, Ox40, 4-1BB, CD2, CD5, CD40, FcgR, FceR, FcaR, and CD95. 5. The nucleic acid molecule of item 4, wherein the immune cell engaging domain targets CD3. 6.a) an amino acid sequence having at least about 90% identity over the entire length of the amino acid sequence to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74 or SEQ ID NO:76; b) a fragment of an amino acid sequence having at least about 90% identity over at least 65% of the amino acid sequence to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74 or SEQ ID NO:76; c) an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74 or SEQ ID NO:76; d) a fragment of an amino acid sequence comprising at least 65% of an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74 or SEQ ID NO:76. The nucleic acid molecule according to item 1, comprising a nucleotide sequence encoding one or more sequences selected from the group consisting of: 7.a) a nucleotide sequence having at least about 90% identity over the entire length of the nucleic acid sequence to a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, and SEQ ID NO:75; b) a fragment of a nucleotide sequence having at least about 90% identity over at least 65% of the nucleic acid sequence to a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, and SEQ ID NO:75; c) a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, and SEQ ID NO:75; d) a fragment of a nucleotide sequence comprising at least 65% of a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, and SEQ ID NO:75. 8. The nucleic acid molecule according to any of items 1 to 7, wherein the nucleotide sequence is operably linked to a nucleic acid sequence encoding an IgE leader sequence. 9. The nucleic acid molecule according to any one of items 1 to 8, wherein the nucleic acid molecule comprises an expression vector. 10. A composition comprising the nucleic acid molecule according to any one of items 1 to 9. 11. The composition according to item 10, further comprising a pharma- ceutically acceptable excipient. 12. A method for preventing or treating a disease or disorder in a subject, the method comprising administering to the subject a nucleic acid molecule according to any of items 1 to 9 or a composition according to any of items 10 to 11. 13. The method according to item 12, wherein the disease is selected from the group consisting of benign tumors, cancer, and cancer-related diseases. 14. A nucleic acid molecule encoding one or more synthetic antibodies, comprising: a) a nucleotide sequence encoding an anti-human epidermal growth factor receptor 2 (HER2) synthetic antibody; b) a nucleotide sequence encoding a fragment of an anti-HER2 synthetic antibody; c) a nucleotide sequence encoding an ScFv anti-HER2 synthetic antibody; d) a nucleotide sequence encoding a fragment of an ScFv anti-HER2 synthetic antibody. 15.a) an amino acid sequence having at least about 90% identity over the entire length of the amino acid sequence to an amino acid sequence selected from the group consisting of SEQ ID NO:62, SEQ ID NO:64, and SEQ ID NO:66; b) a fragment of an amino acid sequence having at least about 90% identity over at least 65% of the amino acid sequence to an amino acid sequence selected from the group consisting of SEQ ID NO: 62, SEQ ID NO: 64, and SEQ ID NO: 66; and c) an amino acid sequence selected from the group consisting of SEQ ID NO:62, SEQ ID NO:64, and SEQ ID NO:66; d) a fragment of an amino acid sequence comprising at least 65% of an amino acid sequence selected from the group consisting of SEQ ID NO: 62, SEQ ID NO: 64, and SEQ ID NO: 66; and 16.a) a nucleotide sequence having at least about 90% identity over the entire length of the nucleic acid sequence to a nucleotide sequence selected from the group consisting of SEQ ID NO:61, SEQ ID NO:63, and SEQ ID NO:65; b) a fragment of a nucleotide sequence having at least about 90% identity over at least 65% of the nucleic acid sequence to a nucleotide sequence selected from the group consisting of SEQ ID NO:61, SEQ ID NO:63, and SEQ ID NO:65; and c) a nucleotide sequence selected from the group consisting of SEQ ID NO:61, SEQ ID NO:63, and SEQ ID NO:65; d) a fragment of a nucleotide sequence comprising at least 65% of a nucleotide sequence selected from the group consisting of SEQ ID NO: 61, SEQ ID NO: 63, and SEQ ID NO: 65. 17. The nucleic acid molecule according to any of items 14 to 16, wherein the nucleotide sequence is operably linked to a nucleic acid sequence encoding an IgE leader sequence. 18. The nucleic acid molecule according to any one of items 14 to 17, wherein the nucleic acid molecule comprises an expression vector. 19. A composition comprising a nucleic acid molecule according to any one of items 14 to 18. 20. The composition according to item 19, further comprising a pharma- ceutically acceptable excipient. 21. A method for preventing or treating a disease in a subject, comprising administering to the subject a nucleic acid molecule according to any of items 14 to 18 or a composition according to any of items 19 to 20. 22. The method according to item 21, wherein the disease is a cancer associated with HER2 expression. 23. The method according to item 22, wherein the disease is ovarian cancer or breast cancer.

Claims

1. 1. A nucleic acid molecule encoding a synthetic DNA-encoded CD19xCD3 bispecific immune cell engager (BITE), said synthetic DNA-encoded bispecific immune cell engager comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:

5.

2. The nucleic acid molecule of claim 1 , wherein the nucleotide sequence is operably linked to a nucleic acid sequence encoding an IgE leader sequence.

3. The nucleic acid molecule of claim 1 or 2, wherein the nucleic acid molecule comprises an expression vector.

4. A composition comprising the nucleic acid molecule according to any one of claims 1 to 3.

5. The composition of claim 4 further comprising a pharma- ceutically acceptable excipient.

6. A nucleic acid molecule according to any one of claims 1 to 3 or a composition according to claim 4 or 5 for preventing or treating a disease or disorder.

7. The nucleic acid molecule or composition of claim 6, wherein the disease is selected from the group consisting of benign tumors, cancer, and cancer-related diseases.

Images